



(11) **EP 2 981 269 B9**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Description Paragraph(s) 113, 115**

(48) Corrigendum issued on:  
**06.12.2023 Bulletin 2023/49**

(45) Date of publication and mention  
of the grant of the patent:  
**09.08.2023 Bulletin 2023/32**

(21) Application number: **14714274.9**

(22) Date of filing: **01.04.2014**

(51) International Patent Classification (IPC):  
**A61K 31/70** <sup>(2006.01)</sup> **A61P 3/00** <sup>(2006.01)</sup>  
**A61P 3/04** <sup>(2006.01)</sup> **A61P 3/10** <sup>(2006.01)</sup>  
**A61K 9/02** <sup>(2006.01)</sup> **A61K 9/20** <sup>(2006.01)</sup>  
**A61K 9/48** <sup>(2006.01)</sup> **A61K 9/00** <sup>(2006.01)</sup>  
**C07H 15/207** <sup>(2006.01)</sup>

(52) Cooperative Patent Classification (CPC):  
**A61K 31/7034; A61K 9/0019; A61K 9/0031;**  
**A61K 9/02; A61K 9/2018; A61K 9/4866;**  
**A61K 31/70; A61K 31/7042; A61K 31/7048;**  
**A61K 31/7056; A61P 3/00; A61P 3/04; A61P 3/10;**  
**C07H 15/207**

(86) International application number:  
**PCT/EP2014/056497**

(87) International publication number:  
**WO 2014/161836 (09.10.2014 Gazette 2014/41)**

(54) **TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS**

BEHANDLUNG VON STOFFWECHSELERKRANKUNGEN BEI PFERDEN

TRAITEMENT DE TROUBLES MÉTABOLIQUES CHEZ DES ÉQUIDÉS

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**

(30) Priority: **04.04.2013 EP 13162408**

(43) Date of publication of application:  
**10.02.2016 Bulletin 2016/06**

(60) Divisional application:  
**23185606.3 / 4 245 765**

(73) Proprietor: **Boehringer Ingelheim Vetmedica**  
**GmbH**  
**55216 Ingelheim am Rhein (DE)**

(72) Inventors:  
• **REICHE, Dania Birte**  
**55216 Ingelheim Am Rhein (DE)**

• **JOHNSTON, Laura**  
**55216 Ingelheim Am Rhein (DE)**

• **MOHREN, Nicole**  
**55216 Ingelheim Am Rhein (DE)**

(74) Representative: **Simon, Elke Anna Maria et al**  
**Boehringer Ingelheim GmbH**  
**Binger Strasse 173**  
**55216 Ingelheim am Rhein (DE)**

(56) References cited:  
**EP-A1- 2 048 150** **WO-A1-2007/128749**  
**WO-A1-2008/116179** **WO-A1-2010/023594**  
**WO-A2-2010/048358**

• **N. Frank ET AL: "Equine Metabolic Syndrome",**  
**Journal of Veterinary Internal Medicine, vol. 24,**  
**no. 3, 2 April 2010 (2010-04-02), pages 467-475,**  
**XP055174732, ISSN: 0891-6640, DOI:**  
**10.1111/j.1939-1676.2010.0503.x**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 2 981 269 B9**

**Description****FIELD OF THE INVENTION**

5 **[0001]** The present invention relates to veterinary medicine, in particular to the treatment and/or prevention of metabolic disorders in equine animals.

**BACKGROUND OF THE INVENTION**

10 **[0002]** Equine animals, e.g. horses, are affected by various metabolic disorders, including insulin resistance and hyperinsulinaemia. Such insulin-related disorders in equine animals, for example, are only rarely associated with diabetes mellitus and hyperglycaemia as it is in humans or various other mammals. However, in equine animals, insulin also regulates vital metabolic functions; e.g. insulin drives glucose into tissues such as liver, adipose, and skeletal muscle; induces vasoconstrictive and vasodilatory pathways; and regulates protein and fat metabolism. Insulin-related disorders  
15 thus have a severe and life-threatening impact on the health of equine animals. They are correlated or may be associated with a number of further equine disorders, conditions or syndromes, including impaired glucose tolerance, dyslipidaemia, dysadipokinemia, obesity and/or regional adiposity, subclinical inflammation or systemic inflammation, in particular low grade systemic inflammation, which also comprises adipose tissue.

20 **[0003]** No satisfactory treatment is currently available for metabolic disorders such as insulin resistance, hyperinsulinaemia and associated disorders in equine animals.

**[0004]** In human medicine, insulin resistance, e.g. when manifest as diabetes mellitus type 2, is a well-recognised condition, and may lead in particular to hyperglycaemia (pathologically increased plasma glucose levels). Several oral antihyperglycaemic drugs are approved for human diabetes. These drugs act, e.g. by stimulating pancreatic insulin  
25 secretion in a glucose-independent or glucose-dependent manner (sulfonylurea/meglitinides, or DPP IV inhibitors, respectively), by enhancing tissue sensitivity to insulin (biguanides, thiazolidinediones), or by slowing postprandial intestinal glucose absorption (alpha-glucosidase inhibitors).

**[0005]** Other antihyperglycaemic approaches have been contemplated for treating diabetes and high blood sugar, including inhibition of the renal sodium-dependent glucose cotransporter SGLT2. SGLT2 in the kidney regulates glucose levels by mediating the reabsorption of glucose back into the plasma following filtration of the blood. SGLT2 inhibition  
30 thus induces glucosuria and may reduce blood glucose levels.

**[0006]** SGLT2 inhibition has not previously been contemplated for use in equine animals, in particular in insulin-resistant equine animals. In equine animals, insulin-resistance, i.e. failure of tissues to respond appropriately to insulin, generally becomes manifest as hyperinsulinaemia. When insulin-resistant target tissues, e.g. skeletal muscle, have a reduced capacity for glucose uptake, the pancreas is stimulated to release more insulin, leading to hyperinsulinaemia. However,  
35 unlike in humans, e.g., insulin resistance in equine animals, e.g. horses, is generally not associated with hyperglycaemia (Frank et al., 2010). Insulin-resistant equine animals, e.g. horses, do not appear to have high blood glucose. For that reason, it would appear to be counterintuitive to apply an approach that reduces blood glucose by transferring glucose out of the blood into the urine, even if this was previously known in a context of high blood glucose.

40 **[0007]** Further prior art are as follows:

WO 2007/128749 A1 discloses glucopyranosyl-substituted benzonitrile derivatives defined according to the respective formula I, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof.

WO 2010/092123 A1 discloses the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor.

**DISCLOSURE OF THE INVENTION****Summary of the invention**

50 **[0008]** The present inventors have surprisingly found that inhibition of SGLT2 is effective and safe in the treatment and/or prevention of metabolic disorders in equine animals. The present invention thus provides a specific SGLT2 inhibitor or a pharmaceutically acceptable form thereof as claimed for use in the treatment and/or prevention of a metabolic disorder of an equine animal. Further aspects of the invention are defined below as well as in the claims.

**[0009]** According to the invention, the metabolic disorder may be insulin resistance, hyperinsulinemia, and/or a clinical  
55 condition associated with insulin resistance and/or hyperinsulinaemia.

**[0010]** The metabolic disorder, or said clinical condition associated with insulin resistance and/or hyperinsulinaemia, may be one or more disorder selected from insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, which also com-

prises adipose tissue, obesity, and/or regional adiposity.

**[0011]** According to the invention, the equine animal may be suffering from one or more of impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, which also comprises adipose tissue, obesity, and/or regional adiposity.

**[0012]** According to the invention, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, which also comprises adipose tissue, obesity, regional adiposity may be associated with hyperinsulinemia and/or insulin resistance

**[0013]** According to the invention, the metabolic disorder may be hyperinsulinemia and/or insulin resistance, and said hyperinsulinemia or insulin resistance may optionally be associated with one or more of impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, which also comprises adipose tissue, obesity, and/or regional adiposity.

**[0014]** The equine animal may, e.g., be a horse. The equine animal may, e.g., be a pony. The equine animal may be obese and/or exhibit regional adiposity.

**[0015]** The pharmaceutically acceptable form of the SGLT2 inhibitor may be a crystalline complex between the SGLT2 inhibitor and one or more amino acids, e.g. proline.

**[0016]** According to the invention, the SGLT2 inhibitor or pharmaceutically acceptable form thereof may be provided, e.g., for oral or parenteral administration, preferably for oral administration.

**[0017]** The SGLT2 inhibitor or a pharmaceutically acceptable form thereof may be administered in dosages of 0.01 to 3.0 mg/kg body weight per day, preferably from 0.02 to 1.0 mg/kg body weight per day, more preferably from 0.03 to 0.4 mg/kg body weight per day. Thus, the SGLT2 inhibitor or pharmaceutically acceptable form thereof may be prepared for the administration of 0.01 to 3.0 mg/kg body weight per day, preferably from 0.02 to 1.0 mg/kg body weight per day, more preferably from 0.03 to 0.4 mg/kg body weight per day.

**[0018]** The SGLT2 inhibitor or pharmaceutically acceptable form thereof is preferably administered only once per day.

**[0019]** The present invention also provides a pharmaceutical composition comprising the SGLT2 inhibitor or a pharmaceutically acceptable form thereof as claimed, for use according to the invention as disclosed herein.

**[0020]** In the examples provided herein, therapeutic and prophylactic benefits resulting from inhibition of SGLT2 according to the present invention are demonstrated experimentally. Experimental data disclosed herein are intended to illustrate the invention, but not to have any limiting effect upon the scope of protection, which is defined herein below by the claims.

**[0021]** In particular, the present inventors have surprisingly found that the use of the SGLT2 inhibitor according to the present invention as claimed advantageously leads to a reduction in insulin resistance in treated, insulin resistant equine animals. That is, equivalently, the use of the SGLT2 inhibitor according to the present invention as claimed advantageously leads to increased insulin sensitivity in treated, insulin resistant equine animals.

**[0022]** The use of the SGLT2 inhibitor according to the present invention as claimed advantageously leads to reduced plasma insulin levels, i.e. allows effective treatment of hyperinsulinaemia. Thus, the use of the SGLT2 inhibitor according to the present invention as claimed advantageously leads to reduced baseline plasma insulin levels, and/or a reduced insulin excursion due to a glycemic challenge, e.g. as measured during an intravenous glucose tolerance test (ivGTT), an oral sugar test (OST) or after any other form of glucose intake, e.g. after a meal (postprandial insulin excursion).

**[0023]** The use of the SGLT2 inhibitor according to the present invention as claimed advantageously leads to a reduction in hyperinsulinemia and surrogate markers of insulin resistance in treated, insulin resistant equine animals.

**[0024]** The glucose excursion after a challenge with insulin (e.g. in an intravenous insulin tolerance test (ivITT)), or after a challenge with glucose (e.g. as measured during an intravenous glucose tolerance test (ivGTT), an oral sugar test (OST) or after any other form of glucose intake, e.g. after a meal (postprandial glucose excursion)), or as measured in a combined glucose-insulin tolerance test (CGIT), of an equine animal treated in accordance with the invention is, advantageously, also improved. That is, after a challenge with insulin, the decrease in glucose levels is greater and/or more rapid; or after a challenge with glucose, the glycemic peak of the glucose excursion is lowered and/or the duration of the glucose excursion is reduced.

**[0025]** The use of the SGLT2 inhibitor according to the present invention as claimed thus generally leads to improved (i.e. increased) glucose tolerance, i.e., equivalently, reduces glucose intolerance.

**[0026]** The use of the SGLT2 inhibitor according to the present invention as claimed advantageously also leads to a reduction in plasma levels of non-esterified fatty acids, or an improved elimination of non-esterified fatty acids (NEFAs) from the bloodstream e.g. after a challenge with insulin (e.g., as measured during an intravenous insulin tolerance test (ivITT)), or after a challenge with glucose (e.g. as measured during an intravenous glucose tolerance test (ivGTT), an oral sugar test (OST) or after any other form of glucose intake, e.g. after a meal, that initiates a blood insulin excursion, or as measured in a combined glucose-insulin tolerance test (CGIT).

**[0027]** The use of the SGLT2 inhibitor according to the present invention as claimed advantageously also leads to a reduction in body fat and improved adipokine profile, e.g. reduced blood leptin levels. The invention is also associated with anti-obesity effects, and/or lead to a decrease in body mass in an equine animal. In one aspect, the invention thus

allows obesity and/or obesity-related metabolic disorders to be managed in an equine animal.

**[0028]** The use of the SGLT2 inhibitor according to the present invention as claimed generally reduces dyslipidaemia, dysadipokinemia, obesity and/or regional adiposity. Thus, the use of the SGLT2 inhibitor as claimed allows the treatment and prevention of dyslipidaemia, dysadipokinemia, obesity and/or regional adiposity, in particular when associated with

insulin resistance and/or hyperinsulinemia in equine animal.

**[0029]** Advantageously, the use of the SGLT2 inhibitor according to the present invention as claimed does not cause hypoglycaemia.

**[0030]** The effects of the uses according to the present invention (i.e. the above-mentioned beneficial effects upon insulin resistance/sensitivity, insulin excursion, second phase insulin secretion, glucose tolerance, elimination of non-esterified fatty acids, body fat, and/or blood leptin levels are also advantageous in that they allow for the prevention of complications of insulin resistance and/or hyperinsulinaemia, and the treatment, prevention or control of further metabolic disorders, symptoms and/or clinical conditions that are associated with insulin resistance and/or hyperinsulinaemia in equine animals. They thus allow the possibility of preventing or delaying the onset of such complications, further metabolic disorders, symptoms and/or clinical conditions in equine animals.

**[0031]** A further advantage of the present invention is that the use of the SGLT2 inhibitor as claimed is effective against the metabolic disorders alone, i.e., if desired the use of the SGLT2 inhibitor as claimed in an equine animal provides a monotherapy (i.e. a stand-alone therapy; i.e., no other medication is administered to the equine animal for the treatment and/or prevention of the same metabolic disorder). The invention also allows for the possibility for combination therapy with another drug (e.g. a further insulin sensitizing drug).

**[0032]** The effects of using the SGLT2 inhibitor according to the present invention as claimed (e.g. the above-mentioned beneficial effects upon insulin resistance/sensitivity, plasma insulin levels, insulin excursion, glucose excursion, glucose tolerance, elimination of non-esterified fatty acids, body fat, and /or blood leptin levels) may be relative to the same or a comparable equine animal prior to administration of the SGLT2 inhibitor according to the present invention as claimed, and/or relative to a comparable equine animal that has not received said treatment (e.g. a placebo group).

**[0033]** A further advantage of the present invention is that the SGLT2 inhibitor as claimed may effectively be administered to an equine animal orally, e.g. in liquid form. Moreover, the SGLT2 inhibitor according to the present invention as claimed can be administered only once per day. These advantages allow for optimal dosing and compliance of the treated equine animal.

**[0034]** Generally, the use of the SGLT2 inhibitor according to the present invention as claimed may thus attenuate, delay or prevent the progression of a metabolic disorder, e.g. the metabolic disorders disclosed herein, or may delay or prevent the onset of metabolic disorders and their complications in equine animals.

**[0035]** The disclosure also provides methods of treating or preventing metabolic disorders in equine animals, comprising administering to an equine animal in need of such treatment and/or prevention an effective dose of the SGLT2 inhibitor as claimed.

## Definitions

**[0036]** All values and concentrations presented herein are subject to inherent variations acceptable in biological science within an error of  $\pm 10\%$ . The term "about" also refers to this acceptable variation.

**[0037]** Treatment effects disclosed herein (such as an improvement, reduction or delayed onset of a disorder, disease or condition, or the improvement, reduction, increase or delay of any effect, index, marker level or other parameter relating to a disorder, disease or condition) may be observed with a statistical significance of  $p < 0.05$ , preferably  $< 0.01$ .

**[0038]** When reference is made herein to a deviation (e.g. an increase, elevation, excess, prolongation, raise, reduction, decrease, improvement, delay, abnormal levels, or any other change, alteration or deviation with respect to a reference), the deviation may be, e.g., by 5% or more, particularly 10% or more, more particularly 15% or more, more particularly 20% or more, more particularly 30% or more, more particularly 40% or more, or more particularly 50% or more, with respect to the relevant reference value, unless otherwise stated. Typically, the deviation will be by at least 10%, i.e. 10% or more. The deviation may also be by 20%. The deviation may also be by 30%. The deviation may also be by 40%. The relevant reference value may be generated from a group of reference animals which are treated with placebo instead of an SGLT2 inhibitor.

**[0039]** Herein, an excursion, e.g. an insulin excursions or glucose excursion, designates a change in concentration or level in blood over time. The magnitude of excursions, e.g. insulin excursions or glucose excursions may be expressed as area-under-curve (AUC) values.

**[0040]** Herein, the terms "active substance" or "active ingredient" encompass the SGLT2 inhibitor or any pharmaceutically acceptable form thereof (e.g. a prodrug or a crystalline form) as claimed, for use according to the invention. In the case of a combination with one or additional active compound, the terms "active ingredient" or "active substance" may also include the additional active compound.

**[0041]** Herein, the expression "associated with", in particular encompasses the expression "caused by".

[0042] Herein, ivGTT refers to an intravenous glucose tolerance test. In an ivGTT, 0.2 g dextrose per kg body mass may typically be employed.

[0043] Herein, ivITT refers to an intravenous insulin tolerance test. In an ivITT, 0.03 U insulin per kg body mass may typically be employed.

5 [0044] Herein, CGIT refers to a combined glucose-insulin tolerance test. In a CGIT, 0.15 mg glucose per kg body mass and 0.1 U insulin per kg body mass may typically be employed.


[0045] Herein, OST refers to an oral sugar test. In an OST, 0.15 mL corn syrup per kg body mass may typically be employed.

## 10 SGLT2 inhibitors

[0046] SGLT2 inhibitors for use according to the disclosure include, but are not limited to, glucopyranosyl-substituted benzene derivatives, for example as described in WO01/27128, WO03/099836, WO2005/092877, WO2006/034489, WO2006/064033, WO2006/117359, WO2006/117360, WO2007/025943, WO2007/028814, WO2007/031548, 15 WO2007/093610, WO2007/128749, WO2008/049923, WO2008/055870, WO2008/055940, WO2009/022020 or WO2009/022008.

[0047] Moreover, a SGLT2 inhibitor for use according to the disclosure may be selected from the group consisting of the following compounds or pharmaceutically acceptable forms thereof:

20 (1) a glucopyranosyl-substituted benzene derivative of the formula (1)



wherein R<sup>1</sup> denotes cyano, Cl or methyl (most preferably cyano);


R<sup>2</sup> denotes H, methyl, methoxy or hydroxy (most preferably H) and

35 R<sup>3</sup> denotes cyclopropyl, hydrogen, fluorine, chlorine, bromine, iodine, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, iso-butyl, tert-butyl, 3-methyl-but-1-yl, cyclobutyl, cyclopentyl, cyclohexyl, 1-hydroxy-cyclopropyl, 1-hydroxy-cyclobutyl, 1-hydroxy-cyclopentyl, 1-hydroxy-cyclohexyl, ethinyl, ethoxy, difluoromethyl, trifluoromethyl, pentafluoroethyl, 2-hydroxyethyl, hydroxymethyl, 3-hydroxy-propyl, 2-hydroxy-2-methyl-prop-1-yl, 3-hydroxy-3-methyl-but-1-yl, 1-hydroxy-1-methyl-ethyl, 2,2,2-trifluoro-1-hydroxy-1-methylethyl, 2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl, 2-methoxy-ethyl, 2-ethoxy-ethyl, hydroxy, difluoromethoxy, trifluoromethoxy, 40 2-methoxy-ethoxy, methylsulfanyl, methylsulfinyl, methylsulfonyl, ethylsulfinyl, ethylsulfonyl, trimethylsilyl, (R)-tetrahydrofuran-3-yloxy or (S)-tetrahydrofuran-3-yloxy or cyano;

wherein R<sup>3</sup> is preferably selected from cyclopropyl, ethyl, ethinyl, ethoxy, (R)-tetrahydrofuran-3-yloxy or (S)-tetrahydrofuran-3-yloxy; and most preferably R<sup>3</sup> is cyclopropyl,


45 or a derivative thereof wherein one or more hydroxyl groups of the  $\beta$ -D-glucopyranosyl group are acylated with groups selected from (C<sub>1-18</sub>-alkyl)carbonyl, (C<sub>1-18</sub>-alkyl)oxycarbonyl, phenylcarbonyl and phenyl-(C<sub>1-3</sub>-alkyl)-carbonyl;

(2) 1-cyano-2-(4-cyclopropyl-benzyl)-4-((3-D-glucopyranos-1-yl)-benzene, represented by formula (2):



(3) Dapagliflozin, represented by formula (3):


5



10

(4) Canagliflozin, represented by formula (4):

15




20

25

(5) Empagliflozin, represented by formula (5):


30



35

(6) Luseogliflozin, represented by formula (6):

40




45


50

55


(7) Tofogliflozin, represented by formula (7):




(8) Ipragliflozin, represented by formula (8):



(9) Ertugliflozin, represented by formula (9):



(10) Atigliflozin, represented by formula (10):




(11) Remogliflozin, represented by formula (11):

5

10


15



(12) a thiophene derivative of the formula (12)

20

25




wherein R denotes methoxy or trifluoromethoxy;

(13) 1-( $\beta$ -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene as described in WO2005/012326, represented by formula (13);

35


40



45

(14) a spiroketal derivative of the formula (14):

50




55

wherein R denotes methoxy, trifluoromethoxy, ethoxy, ethyl, isopropyl or tert. butyl;  
 (15) a pyrazole-O-glucoside derivative of the formula (15)

5

10



wherein

15

$R^1$  denotes  $C_{1-3}$ -alkoxy,


$L^1$ ,  $L^2$  independently of each other denote H or F,

$R^6$  denotes H, ( $C_{1-3}$ -alkyl)carbonyl, ( $C_{1-6}$ -alkyl)oxycarbonyl, phenyloxycarbonyl, benzyloxycarbonyl or benzylcarbonyl;

20

(16) a compound of the formula (16):

25




30

(17) and Sergliflozin, represented by formula (17):

35

40



45 **[0048]** The term "dapagliflozin" as employed herein refers to dapagliflozin of the above structure as well as pharmaceutically acceptable forms thereof, including hydrates and solvates thereof, and crystalline forms thereof. The compound and methods of its synthesis are described in WO03/099836 for example. Preferred hydrates, solvates and crystalline forms are described in the patent applications WO2008/116179 and WO2008/002824 for example.

50 **[0049]** The term "canagliflozin" as employed herein refers to canagliflozin of the above structure as well as pharmaceutically acceptable forms thereof, including hydrates and solvates thereof, and crystalline forms thereof. The compound and methods of its synthesis are described in WO2005/012326 and WO2009/035969 for example. Preferred hydrates, solvates and crystalline forms are described in the patent application WO2008/069327 for example.

55 **[0050]** The term "empagliflozin" as employed herein refers to empagliflozin of the above structure as well as pharmaceutically acceptable forms thereof, including hydrates and solvates thereof, and crystalline forms thereof. The compound and methods of its synthesis are described in WO2005/092877, WO2006/120208 and WO2011/039108 for example. A preferred crystalline form is described in the patent applications WO2006/117359 and WO2011/039107 for example.

**[0051]** The term "atigliflozin" as employed herein refers to atigliflozin of the above structure as well as pharmaceutically acceptable forms thereof, including hydrates and solvates thereof, and crystalline forms thereof. The compound and

methods of its synthesis are described in WO2004/007517 for example.

**[0052]** The term "ipragliflozin" as employed herein refers to ipragliflozin of the above structure as well as pharmaceutically acceptable forms thereof, including hydrates and solvates thereof, and crystalline forms thereof. The compound and methods of its synthesis are described in WO2004/080990, WO2005/012326 and WO2007/114475 for example.

**[0053]** The term "tofogliflozin" as employed herein refers to tofogliflozin of the above structure as well as pharmaceutically acceptable forms thereof, including hydrates and solvates thereof, and crystalline forms thereof. The compound and methods of its synthesis are described in WO2007/140191 and WO2008/013280 for example.

**[0054]** The term "luseogliflozin" as employed herein refers to luseogliflozin of the above structure as well as pharmaceutically acceptable forms thereof, including hydrates and solvates thereof, and crystalline forms thereof.

**[0055]** The term "ertugliflozin" as employed herein refers to ertugliflozin of the above structure as well as pharmaceutically acceptable forms thereof, including hydrates and solvates thereof, and crystalline forms thereof. The compound is described for example in WO2010/023594.


**[0056]** The term "remogliflozin" as employed herein refers to remogliflozin of the above structure as well as pharmaceutically acceptable forms thereof, including prodrugs of remogliflozin, in particular remogliflozin etabonate, including hydrates and solvates thereof, and crystalline forms thereof. Methods of its synthesis are described in the patent applications EP1213296 and EP1354888 for example.

**[0057]** The term "sergliflozin" as employed herein refers to sergliflozin of the above structure as well as pharmaceutically acceptable forms thereof, including prodrugs of sergliflozin, in particular sergliflozin etabonate, including hydrates and solvates thereof, and crystalline forms thereof. Methods for its manufacture are described in the patent applications EP 13447 80 and EP1489089 for example.

**[0058]** The compound of formula (16) above and its manufacture are described for example in WO2008/042688 or WO2009/014970.

**[0059]** According to the disclosure SGLT2 inhibitors are glucopyranosyl-substituted benzene derivatives. Optionally, one or more hydroxyl groups of the glucopyranosyl group in such an SGLT2 inhibitor may be acylated with groups selected from (C<sub>1-18</sub>-alkyl)carbonyl, (C<sub>1-18</sub>-alkyl)oxycarbonyl, phenylcarbonyl and phenyl-(C<sub>1-3</sub>-alkyl)-carbonyl.

**[0060]** According to the disclosure SGLT2 inhibitors are glucopyranosyl-substituted benzonitrile derivatives of formula (1) as disclosed herein above. Yet more preferred are glucopyranosyl-substituted benzonitrile derivatives of formula (18):



wherein

R<sub>3</sub> denotes cyclopropyl, hydrogen, fluorine, chlorine, bromine, iodine, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, iso-butyl, tert-butyl, 3-methyl-but-1-yl, cyclobutyl, cyclopentyl, cyclohexyl, 1-hydroxy-cyclopropyl, 1-hydroxy-cyclobutyl, 1-hydroxy-cyclopentyl, 1-hydroxy-cyclohexyl, ethinyl, ethoxy, difluoromethyl, trifluoromethyl, pentafluoroethyl, 2-hydroxyl-ethyl, hydroxymethyl, 3-hydroxy-propyl, 2-hydroxy-2-methyl-prop-1-yl, 3-hydroxy-3-methyl-but-1-yl, 1-hydroxy-1-methyl-ethyl, 2,2,2-trifluoro-1-hydroxy-1-methyl-ethyl, 2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl, 2-methoxy-ethyl, 2-ethoxyethyl, hydroxy, difluoromethyloxy, trifluoromethyloxy, 2-methoxy-ethoxy, methylsulfanyl, methylsulfinyl, methylsulfonyl, ethylsulfinyl, ethylsulfonyl, trimethylsilyl, (R)-tetrahydrofuran-3-yloxy or (S)-tetrahydrofuran-3-yloxy or cyano (wherein R<sub>3</sub> is preferably selected from cyclopropyl, ethyl, ethinyl, ethoxy, (R)-tetrahydrofuran-3-yloxy or (S)-tetrahydrofuran-3-yloxy; and R<sub>3</sub> most preferably is cyclopropyl),

or a derivative thereof wherein one or more hydroxyl groups of the β-D-glucopyranosyl group are acylated with groups selected from (C<sub>1-18</sub>-alkyl)carbonyl, (C<sub>1-18</sub>-alkyl)oxycarbonyl, phenylcarbonyl and phenyl-(C<sub>1-3</sub>-alkyl)-carbonyl.

**[0061]** According to the present invention, the SGLT2 inhibitor is 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene as shown in formula (2) (also referred to herein as "compound A"). Optionally, one or more hydroxyl groups of the β-D-glucopyranosyl group of compound A may be acylated with groups selected from (C<sub>1-18</sub>-alkyl)carbonyl, (C<sub>1-18</sub>-alkyl)oxycarbonyl, phenylcarbonyl and phenyl-(C<sub>1-3</sub>-alkyl)-carbonyl.

[0062] Thus, according to the present invention, the SGLT2 inhibitor is the glucopyranosyl-substituted benzene derivative SGLT2 inhibitor of formula (2) (i.e. compound A), as defined herein above.

### Metabolic disorders

5

[0063] According to the invention, metabolic disorders or metabolic diseases are all kinds of disturbances of the energy metabolism, affecting e.g. the turnover of carbohydrates and/or of fat. It is preferred to affect the control of the energy metabolism, especially the glucose metabolism by influencing the responsible regulatory network, e.g. via modulation of the activity and/or concentrations of insulin.

10 [0064] The metabolic disorder may be an insulin-related disorder. In particular, the metabolic disorder may be insulin resistance (or, equivalently, impaired insulin sensitivity). Insulin resistance may be associated with a further metabolic disorder or clinical condition, e.g. insulin resistance may be associated with impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, which also comprises adipose tissue, obesity and/or regional adiposity.

15 [0065] The metabolic disorder may be hyperinsulinaemia. Hyperinsulinaemia may be associated with a further metabolic disorder or clinical condition, e.g. hyperinsulinaemia may be associated with obesity and/or regional adiposity.

[0066] In preferred embodiments, the metabolic disorder may be insulin resistance, hyperinsulinemia and/or a clinical condition associated with insulin resistance and/or hyperinsulinaemia. Treatment and/or prevention of a metabolic disorder of an equine animal in accordance with the invention may be treatment and/or prevention of insulin resistance and/or hyperinsulinaemia.

20 [0067] Clinical conditions associated with insulin resistance and/or hyperinsulinaemia are e.g. impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, which also comprises adipose tissue, obesity and/or regional adiposity. Treatment and/or prevention of a metabolic disorder of an equine animal in accordance with the invention may be the treatment and/or prevention of impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, which also comprises adipose tissue, obesity and/or regional adiposity in an equine animal.

25 [0068] Herein, a metabolic disorder or clinical condition, e.g. a metabolic disorder or clinical condition associated with insulin resistance and/or hyperinsulinaemia may be impaired glucose tolerance. Hence, the treatment and/or prevention of a metabolic disorder of an equine animal in accordance with the invention may be the treatment and/or prevention of impaired glucose tolerance, preferably associated with insulin resistance and/or hyperinsulinaemia in an equine animal.

30 [0069] Herein, a metabolic disorder or clinical condition, e.g. a metabolic disorder or clinical condition associated with insulin resistance and/or hyperinsulinaemia may be dyslipidemia. Hence, the treatment and/or prevention of a metabolic disorder of an equine animal in accordance with the invention may be the treatment and/or prevention of dyslipidemia, preferably associated with insulin resistance and/or hyperinsulinaemia in an equine animal.

35 [0070] Herein, a metabolic disorder or clinical condition, e.g. a metabolic disorder or clinical condition associated with insulin resistance and/or hyperinsulinaemia may be dysadipokinemia. Hence, the treatment and/or prevention of a metabolic disorder of an equine animal in accordance with the invention may be treatment and/or prevention of dysadipokinemia, preferably associated with insulin resistance and/or hyperinsulinaemia in an equine animal.

40 [0071] Herein, a metabolic disorder or clinical condition, e.g. a metabolic disorder or clinical condition associated with insulin resistance and/or hyperinsulinaemia may be subclinical inflammation or systemic inflammation, in particular low grade systemic inflammation, which also comprises adipose tissue. Hence, the treatment and/or prevention of a metabolic disorder of an equine animal in accordance with the invention may be treatment and/or prevention of subclinical inflammation or systemic inflammation, in particular low grade systemic inflammation, which also comprises adipose tissue, preferably associated with insulin resistance and/or hyperinsulinaemia in an equine animal.

45 [0072] Herein, a metabolic disorder or clinical condition, e.g. a metabolic disorder or clinical condition associated with insulin resistance and/or hyperinsulinaemia may be obesity. Hence, the treatment and/or prevention of a metabolic disorder of an equine animal in accordance with the invention may be treatment and/or prevention of obesity, preferably associated with insulin resistance and/or hyperinsulinaemia in an equine animal.

50 [0073] Herein, a metabolic disorder or clinical condition, e.g. a metabolic disorder or clinical condition associated with insulin resistance and/or hyperinsulinaemia may be regional adiposity. Hence, the treatment and/or prevention of a metabolic disorder of an equine animal in accordance with the invention may be treatment and/or prevention of regional adiposity, preferably associated with insulin resistance and/or hyperinsulinaemia in an equine animal.

[0074] In some embodiments, impaired glucose tolerance may be associated with obesity and/or regional adiposity. Hence, the treatment and/or prevention of a metabolic disorder of an equine animal in accordance with the invention may be treatment and/or prevention of impaired glucose tolerance associated with obesity and/or regional adiposity in an equine animal.

55 [0075] **Insulin resistance** can be described as the condition in which normal amounts of insulin are inadequate to produce a normal insulin response from fat, muscle and liver cells. Insulin resistance in fat cells reduces the effects of

insulin and results in elevated hydrolysis of stored triglycerides in the absence of measures which either increase insulin sensitivity or which provide additional insulin. Increased mobilization of stored lipids in these cells elevates free fatty acids in the blood plasma. Insulin resistance in muscle cells reduces glucose uptake (and so local storage of glucose as glycogen), whereas insulin resistance in liver cells results in impaired glycogen synthesis and a failure to suppress glucose production. Elevated blood fatty acid levels, reduced muscle glucose uptake, and increased liver glucose production, may all contribute to elevated blood glucose levels (hyperglycaemia), although hyperglycaemia is not a major issue e.g. in insulin-resistant horses. In the horse, when insulin-resistant target tissues, e.g. skeletal muscle, have a reduced capacity for glucose uptake, the pancreas is stimulated to release more insulin, leading to hyperinsulinaemia.

[0076] Surrogate indices of insulin sensitivity may be calculated according to the QUICKI (quantitative insulin sensitivity check index:  $1/\log(\text{glucose} \cdot \text{insulin})$ ) for basal blood level. For dynamic testings, e.g. during a glucose challenge a modified Belfiore Index ( $1/\log(\Delta\text{AUC-glucose} \cdot \Delta\text{AUC-insulin})$ ) can be employed.

[0077] Insulin resistance may be present in association with regional adiposity, e.g. cresty neck, tail fat depots, visceral adiposity, hypertension and dyslipidaemia involving elevated triglycerides, small dense low-density lipoprotein (sdLDL) particles, and decreased HDL cholesterol levels. With respect to visceral adiposity, a great deal of evidence in humans suggests two strong links with insulin resistance. First, unlike subcutaneous adipose tissue, visceral adipose cells produce significant amounts of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF- $\alpha$ ), and Interleukins-1 and -6, etc. In numerous experimental models, these proinflammatory cytokines profoundly disrupt normal insulin action in fat and muscle cells, and may be a major factor in causing the whole-body insulin resistance observed in human patients with visceral adiposity. Similar, in equines the different excessive regional fat depots contribute to low grade systemic inflammation. The cause of the vast majority of cases of insulin resistance remains unknown. There is clearly an inherited component. However, there are some grounds for suspecting that insulin resistance is related to a high-carbohydrate diet. Inflammation also seems to be implicated in causing insulin resistance.

[0078] **Hyperinsulinaemia** can be described as a condition in which there are excess levels, i.e. more than about 10-20  $\mu\text{IU/mL}$  of insulin circulating in the blood. As mentioned, it is commonly present in cases of, and may be a consequence of, insulin resistance in equine animals.

[0079] **Impaired glucose tolerance** can be described as condition in which the response to a after a glycemic challenge e.g. after a meal or after a loading test (glucose tolerance test) the glycemic peak of the glucose excursion is higher and/or the duration of the glucose excursion is prolonged.

[0080] **Dyslipidaemia** or hyperlipidaemia is the presence of raised or abnormal levels of lipids and/or lipoproteins in the blood. Lipid and lipoprotein abnormalities are regarded as a highly modifiable risk factor for cardiovascular disease due to the influence of cholesterol. Glycerol is a precursor for the synthesis of triacylglycerols (triglycerids) and of phospholipids in the liver and adipose tissue. When the body uses stored fat as a source of energy, glycerol and fatty acids are released into the bloodstream after hydrolysis of the triglycerides. The glycerol component can be converted to glucose by the liver and provides energy for cellular metabolism. Normal levels of free fatty acids in the blood equine animals are concentrations of 50 to 100 mg/dl (0.6 to 1.2 mmol/l). Normal levels of triglycerides are e.g. up to around 50 mg/dL. Normal levels of blood cholesterol are, e.g., around 120 mg/dl for the horse.

[0081] **Dysadipokinemia** can be described as a condition in which the circulating plasma levels of biologically active substances produced in adipose tissue that act in an autocrine/paracrine or endocrine fashion is deviated, e.g. an elevation of leptin and/or a reduction of adiponectin.

[0082] **Subclinical inflammation or systemic inflammation**, in particular **low grade systemic inflammation** is characterized by increased expression and secretion of pro-inflammatory cytokines such as tumor necrosis factor-alpha and/or and/or lower expression and secretion of anti-inflammatory cytokines e.g. interleukin-10 and/or their respective receptors.

[0083] **Obesity** can be described as a medical condition in which excess body fat has accumulated to the extent that it may have an adverse effect on health, leading to reduced life expectancy. In equines e.g. during physical examination a body condition scores of equal or more than 7 (out of 9) is encountered.

[0084] **Regional adiposity** in equine animals can be described as a medical condition in which body fat (adipose tissue) accumulates in specific regions, e.g. the neck (cresty neck), either side of the tailhead, prepuce, in fat pads in the rump area, the mammary gland region, and/or in supraorbital fat pads. Regional adiposity also encompasses visceral adiposity, e.g. increased omental fat.

## Equine animals

[0085] Herein, the term "equine animal" may be used interchangeably with the term "equine" and encompasses any member of the genus *Equus*. It encompasses, e.g., any horse or pony, the taxonomic designations *Equus ferus* and/or *Equus caballus*, and/or the subspecies *Equus ferus caballus*. The equine animal may, e.g., be a domestic horse.

## Pharmaceutically acceptable forms

**[0086]** Herein, references to the SGLT2 inhibitor as claimed and/or its use according to the invention encompass pharmaceutically acceptable forms of the SGLT2 inhibitor, unless otherwise stated.

**[0087]** According to the invention, any pharmaceutically acceptable form of the SGLT2 inhibitor (of formula (2), may be used. E.g. a crystalline form may be used. Prodrug forms are also encompassed by the present invention.

**[0088]** Prodrug forms may include, e.g., esters and/or hydrates. The term pro-drug is also meant to include any covalently bonded carrier which releases the active compound of the invention in vivo when the prodrug is administered to a mammalian subject. Pro-drugs of a compound of the invention may be prepared by modifying functional groups present in the compound of the invention in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound of the invention.

**[0089]** Crystalline forms for use according to the invention include a complex of the SGLT2 inhibitor as claimed with one or more amino acids (see e.g. WO 2014/016381). An amino acid for such use may be a natural amino acid. The amino acid may be a proteogenic amino acid (including L-hydroxyproline), or a non-proteogenic amino acid. The amino acid may be a D- or an L-amino acid. In some preferred embodiments the amino acid is proline (L-proline and/or D-proline, preferably L-proline). E.g., a crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzene (formula (2); compound A) with proline (e.g. L-proline) is preferred.

**[0090]** Thus, herein is disclosed a crystalline complex between one or more natural amino acids and the SGLT2 inhibitor as claimed, e.g., a crystalline complex between one or more natural amino acids and a glucopyranosyl-substituted benzene derivative SGLT2 inhibitor of formula (2) (compound A). Thus, herein is disclosed a crystalline complex between one or more natural amino acids and 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzene (compound A).

**[0091]** Further disclosed herein is the use of one or more crystalline complexes as defined hereinbefore or hereinafter for preparing a pharmaceutical composition which is suitable for the treatment and/or prevention of diseases or conditions which can be influenced by inhibiting sodium-dependent glucose cotransporter SGLT, preferably SGLT2. Further disclosed herein is the use of one or more crystalline complexes as defined hereinbefore or hereinafter for preparing a pharmaceutical composition for inhibiting the sodium-dependent glucose cotransporter SGLT2.

**[0092]** A crystalline complex between one or more natural amino acids (e.g. proline, preferably L-proline) and an SGLT2 inhibitor, is a preferred pharmaceutically acceptable form of the SGLT2 inhibitor as claimed for use according to the present invention. In particular, a crystalline complex between one or more natural amino acids (e.g. proline, preferably L-proline) and the glucopyranosyl-substituted benzene derivative SGLT2 inhibitor of formula (2) (compound A) is a preferred pharmaceutically acceptable form of the SGLT2 inhibitor for use according to the present invention. A crystalline complex between one or more natural amino acids (e.g. proline, preferably L-proline) and 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzene (compound A) is particularly preferred as a pharmaceutically acceptable form of the SGLT2 inhibitor for use according to the present invention.

**[0093]** Also disclosed herein is a method for making one or more crystalline complexes as defined hereinbefore and hereinafter, said method comprising the following steps:

- (a) preparing a solution of the SGLT2 inhibitor and the one or more natural amino acids in a solvent or a mixture of solvents;
- (b) storing the solution to precipitate the crystalline complex out of solution;
- (c) removing the precipitate from the solution; and
- (d) drying the precipitate optionally until any excess of said solvent or mixture of solvents has been removed.

**[0094]** A certain pharmaceutical activity is of course the basic prerequisite to be fulfilled by a pharmaceutically active agent before same is approved as a medicament on the market. However, there are a variety of additional requirements a pharmaceutically active agent has to comply with. These requirements are based on various parameters which are connected with the nature of the active substance itself. Without being restrictive, examples of these parameters are the stability of the active agent under various environmental conditions, its stability during production of the pharmaceutical formulation and the stability of the active agent in the final medicament compositions. The pharmaceutically active substance used for preparing the pharmaceutical compositions should be as pure as possible and its stability in long-term storage must be guaranteed under various environmental conditions. This is essential to prevent the use of pharmaceutical compositions which contain, in addition to the actual active substance, breakdown products thereof, for example. In such cases the content of active substance in the medicament might be less than that specified.

**[0095]** Uniform distribution of the medicament in the formulation is a critical factor, particularly when the medicament has to be given in low doses. To ensure uniform distribution, the particle size of the active substance can be reduced to a suitable level, e.g. by grinding. Since breakdown of the pharmaceutically active substance as a side effect of the grinding (or micronising) has to be avoided as far as possible, in spite of the hard conditions required during the process,

it is essential that the active substance should be highly stable throughout the grinding process. Only if the active substance is sufficiently stable during the grinding process it is possible to produce a homogeneous pharmaceutical formulation which always contains the specified amount of active substance in a reproducible manner.

5 [0096] Another problem which may arise in the grinding process for preparing the desired pharmaceutical formulation is the input of energy caused by this process and the stress on the surface of the crystals. This may in certain circumstances lead to polymorphous changes, to amorphization or to a change in the crystal lattice. Since the pharmaceutical quality of a pharmaceutical formulation requires that the active substance should always have the same crystalline morphology, the stability and properties of the crystalline active substance are subject to stringent requirements from this point of view as well.

10 [0097] The stability of a pharmaceutically active substance is also important in pharmaceutical compositions for determining the shelf life of the particular medicament; the shelf life is the length of time during which the medicament can be administered without any risk. High stability of a medicament in the abovementioned pharmaceutical compositions under various storage conditions is therefore an additional advantage for both the patient and the manufacturer.

15 [0098] The absorption of moisture reduces the content of pharmaceutically active substance as a result of the increased weight caused by the uptake of water. Pharmaceutical compositions with a tendency to absorb moisture have to be protected from moisture during storage, e.g. by the addition of suitable drying agents or by storing the drug in an environment where it is protected from moisture. Preferably, therefore, a pharmaceutically active substance should be at best slightly hygroscopic.

20 [0099] Furthermore, the availability of a well-defined crystalline form allows the purification of the drug substance by recrystallization.

[0100] Apart from the requirements indicated above, it should be generally borne in mind that any change to the solid state of a pharmaceutical composition which is capable of improving its physical and chemical stability gives a significant advantage over less stable forms of the same medicament.

25 [0101] A crystalline complex between a natural amino acid and the SGLT2 inhibitor as claimed fulfills important requirements mentioned hereinbefore.

[0102] Preferably the natural amino acid is present in either its (D) or (L) enantiomeric form, most preferably as the (L) enantiomer.

30 [0103] Furthermore those crystalline complexes according to this invention are preferred which are formed between the SGLT2 inhibitor and one natural amino acid, most preferably between the compound A and the (L) enantiomer of a natural amino acid.

[0104] Preferred amino acids according to this invention are selected from the group consisting of phenylalanine and proline, in particular (L)-proline and (L)-phenylalanine.

[0105] According to a preferred embodiment the crystalline complex is characterized in that the natural amino acid is proline, in particular (L)-proline.

35 [0106] Preferably the molar ratio of the SGLT2 inhibitor and the natural amino acid is in the range from about 2 : 1 to about 1 : 3; more preferably from about 1.5 : 1 to about 1 : 1.5, even more preferably from about 1.2 : 1 to about 1 : 1.2, most preferably about 1 : 1. In the following such an embodiment is referred to as "complex (1 : 1)" or "1 : 1 complex".

[0107] Therefore a preferred crystalline complex according to this invention is a complex (1 : 1) between said SGLT2 inhibitor and proline; in particular of said SGLT2 inhibitor and L-proline.

40 [0108] According to a preferred embodiment the crystalline complex, in the particular the 1 : 1 complex of said SGLT2 inhibitor with L-proline, is a hydrate.

[0109] Preferably the molar ratio of the crystalline complex and water is in the range from about 1 : 0 to 1 : 3; more preferably from about 1 : 0 to 1 : 2, even more preferably from about 1 : 0.5 to 1 : 1.5, most preferably about 1 : 0.8 to 1 : 1.2, in particular about 1:1.

45 [0110] The crystalline complex of said SGLT2 inhibitor with proline, in particular with L-proline and water, may be identified and distinguished from other crystalline forms by means of their characteristic X-ray powder diffraction (XRPD) patterns.

[0111] For example, a crystalline complex of compound A with L-proline is preferably characterised by an X-ray powder diffraction pattern that comprises peaks at 20.28, 21.14 and 21.64 degrees  $2\Theta$  ( $\pm 0.1$  degrees  $2\Theta$ ), wherein said X-ray powder diffraction pattern is made using  $\text{CuK}_{\alpha 1}$  radiation.

50 [0112] In particular said X-ray powder diffraction pattern comprises peaks at 4.99, 20.28, 21.14, 21.64 and 23.23 degrees  $2\Theta$  ( $\pm 0.1$  degrees  $2\Theta$ ), wherein said X-ray powder diffraction pattern is made using  $\text{CuK}_{\alpha 1}$  radiation.

[0113] More specifically said X-ray powder diffraction pattern comprises peaks at 4.99, 17.61, 17.77, 20.28, 21.14, 21.64, 23.23 and 27.66 degrees  $2\Theta$  ( $\pm 0.1$  degrees  $2\Theta$ ), wherein said X-ray powder diffraction pattern is made using  $\text{CuK}_{\alpha 1}$  radiation.

55 [0114] Even more specifically said X-ray powder diffraction pattern comprises peaks at 4.99, 15.12, 17.61, 17.77, 18.17, 20.28, 21.14, 21.64, 23.23 and 27.66 degrees  $2\Theta$  ( $\pm 0.1$  degrees  $2\Theta$ ), wherein said X-ray powder diffraction pattern is made using  $\text{CuK}_{\alpha 1}$  radiation.

EP 2 981 269 B9

[0115] Even more specifically, the crystalline complex of compound A and L-proline is characterised by an X-ray powder diffraction pattern, made using  $\text{CuK}_{\alpha 1}$  radiation, which comprises peaks at degrees  $2\Theta$  ( $\pm 0.1$  degrees  $2\Theta$ ) as contained in Table 1.

5 **Table 1:** X-ray powder diffraction pattern of the crystalline complex of compound A and L-proline (only peaks up to  $30^\circ$  in  $2\Theta$  are listed):

$2\Theta$ [°]	d-value [Å]	Intensity $I/I_0$ [%]
4.99	17.68	39
7.01	12.61	6
8.25	10.70	11
9.95	8.88	12
13.15	6.73	30
13.33	6.64	10
14.08	6.28	4
15.12	5.85	32
16.40	5.40	12
16.49	5.37	13
17.11	5.18	6
17.61	5.03	32
17.77	4.99	35
18.17	4.88	32
18.32	4.84	28
18.72	4.74	8
19.16	4.63	30
19.96	4.45	26
20.28	4.37	56
20.60	4.31	7
21.14	4.20	84
21.64	4.10	100
22.33	3.98	15
23.23	3.83	41
24.06	3.70	4
24.51	3.63	15
24.93	3.57	26
25.89	3.44	23
26.21	3.40	11
26.84	3.32	8
27.66	3.22	38
27.96	3.19	9
28.26	3.16	5
28.44	3.14	6

(continued)

2 $\Theta$ [°]	d-value [Å]	Intensity I/I <sub>0</sub> [%]
28.75	3.10	6
29.18	3.06	19

**[0116]** Even more specifically, said crystalline complex is characterised by an X-ray powder diffraction pattern, made using CuK <sub>$\alpha$ 1</sub> radiation, which comprises peaks at degrees 2 $\Theta$  ( $\pm 0.1$  degrees 2 $\Theta$  as shown in Figure 13.

**[0117]** Furthermore said crystalline complex of the compound A with L-proline is characterised by a melting point of above 89°C, in particular in a range from about 89°C to about 115°C, more preferably in a range from about 89°C to about 110°C (determined via DSC; evaluated as onset-temperature; heating rate 10 K/min). It can be observed that this crystalline complex melts under dehydration. The obtained DSC curve is shown in Figure 14.

**[0118]** Said crystalline complex of the compound A with L-proline shows a weight loss by thermal gravimetry (TG). The observed weight loss indicates that the crystalline form contains water which may be bound by adsorption and/or may be part of the crystalline lattice, i.e. the crystalline form may be present as a crystalline hydrate. The content of water in the crystalline form lies in the range from 0 to about 10 weight-%, in particular 0 to about 5 weight-%, even more preferably from about 1.5 to about 5 weight-%. The dotted line depicts a weight loss of between 2.8 and 3.8 % of water. From the observed weight loss a stoichiometry close to a monohydrate can be estimated.

**[0119]** Said crystalline complex has advantageous physico-chemical properties which are beneficial in the preparation of a pharmaceutical composition. In particular the crystalline complex has a high physical and chemical stability under various environmental conditions and during the production of a medicament. For example the crystals can be obtained in a shape and particle size which are particular suitable in a production method for solid pharmaceutical formulations. In addition the crystals show a high mechanical stability that allows grinding of the crystals. Furthermore the crystalline complex does not show a high tendency to absorb moisture and is chemically stable, i.e. the crystalline complex allows the production of a solid pharmaceutical formulation with a long shelf life. On the other hand the crystalline complex has a favorably high solubility over a wide pH-range which is advantageous in solid pharmaceutical formulations for oral administration.

**[0120]** The X-ray powder diffraction patterns may be recorded using a STOE - STADI P-diffractometer in transmission mode fitted with a location-sensitive detector (OED) and a Cu-anode as X-ray source (CuK <sub>$\alpha$ 1</sub> radiation,  $\lambda = 1.54056 \text{ \AA}$ , 40kV, 40mA). In Table 1 the values "2 $\Theta$  [°]" denote the angle of diffraction in degrees and the values "d [Å]" denote the specified distances in Å between the lattice planes. The intensity shown in Figure 13 is given in units of cps (counts per second).

**[0121]** In order to allow for experimental error, the above described 2  $\Theta$  values should be considered accurate to  $\pm 0.1$  degrees 2  $\Theta$ , in particular  $\pm 0.05$  degrees 2  $\Theta$ . That is to say, when assessing whether a given sample of crystals of the compound A is the crystalline form in accordance with the above described 2  $\Theta$  values, a 2  $\Theta$  value which is experimentally observed for the sample should be considered identical with a characteristic value described above if it falls within  $\pm 0.1$  degrees 2  $\Theta$  of the characteristic value, in particular if it falls within  $\pm 0.05$  degrees 2  $\Theta$  of the characteristic value.

**[0122]** The melting point is determined by DSC (Differential Scanning Calorimetry) using a DSC 821 (Mettler Toledo). The weight loss is determined by thermal gravimetry (TG) using a TGA 851 (Mettler Toledo).

**[0123]** Also disclosed herein is a method for making a crystalline complex as defined hereinbefore and hereinafter, said method comprising the following steps:

- (a) preparing a solution of the SGLT2 inhibitor as claimed and the one or more natural amino acids in a solvent or a mixture of solvents;
- (b) storing the solution to precipitate the crystalline complex out of solution;
- (c) removing the precipitate from the solution; and
- (d) drying the precipitate optionally until any excess of said solvent or mixture of solvents has been removed.

**[0124]** According to step (a) a solution of the SGLT2 inhibitor and the one or more natural amino acids in a solvent or a mixture of solvents is prepared. Preferably the solution is saturated or at least nearly saturated or even supersaturated with respect to the crystalline complex. In the step (a) the SGLT2 inhibitor may be dissolved in a solution comprising the one or more natural amino acids or the one or more natural amino acids may be dissolved in a solution comprising the SGLT2 inhibitor. According to an alternative procedure the SGLT2 inhibitor is dissolved in a solvent or mixture of solvents to yield a first solution and the one or more natural amino acids are dissolved in a solvent or mixture of solvents to yield

a second solution. Thereafter said first solution and said second solution are combined to form the solution according to step (a).

**[0125]** Preferably the molar ratio of the natural amino acid and the SGLT2 inhibitor in the solution corresponds to the molar ratio of the natural amino acid and the SGLT2 inhibitor in the crystalline complex to be obtained. Therefore a preferred molar ratio is in the range from about 1 : 2 to 3 : 1; most preferably about 1:1.

**[0126]** Suitable solvents are preferably selected from the group consisting of C<sub>1-4</sub>-alkanols, water, ethylacetate, acetonitrile, acetone, diethylether, tetrahydrofuran, and mixture of two or more of these solvents.

**[0127]** More preferred solvents are selected from the group consisting of methanol, ethanol, isopropanol, water and mixture of two or more of these solvents, in particular mixtures of one or more of said organic solvents with water.

**[0128]** Particularly preferred solvents are selected from the group consisting of ethanol, isopropanol, water and mixtures of ethanol and/or isopropanol with water.

**[0129]** In case a mixture of water and one or more C<sub>1-4</sub>-alkanols, in particular of methanol, ethanol and/or isopropanol, most preferably of ethanol, is taken, a preferred volume ratio of water : the alkanol is in the range from about 99 : 1 to 1 : 99; more preferably from about 50 : 1 to 1 : 80; even more preferably from about 10 : 1 to 1 : 60.

**[0130]** Preferably the step (a) is carried out at about room temperature (about 20°C) or at an elevated temperature up to about the boiling point of the solvent or mixture of solvents used.

**[0131]** According to a preferred embodiment the starting material of the SGLT2 inhibitor and/or of the one or more natural amino acids and/or of the solvent and mixtures of solvents contain an amount of H<sub>2</sub>O which is at least the quantity required to form a hydrate of the SGLT2 inhibitor; in particular at least 1 mol, preferably at least 1.5 mol of water per mol of SGLT2 inhibitor. Even more preferably the amount of water is at least 2 mol of water per mol of SGLT2 inhibitor. This means that either the SGLT2 inhibitor (compound A) as starting material or the one or more natural amino acids or said solvent or mixture of solvents, or said compounds and/or solvents in combination contain an amount of H<sub>2</sub>O as specified above. For example if the starting material of the SGLT2 inhibitor (compound A) or of the natural amino acid in step (a) does contain sufficient water as specified above, a water content of the solvent(s) is not mandatory.

**[0132]** In order to reduce the solubility of the crystalline complex according to this invention in the solution, in step (a) and/or in step (b) one or more antisolvents may be added, preferably during step (a) or at the beginning of step (b). Water is an example of a suitable antisolvent. The amount of antisolvent is preferably chosen to obtain a supersaturated or saturated solution with respect to the crystalline complex.

**[0133]** In step (b) the solution is stored for a time sufficient to obtain a precipitate, i.e. the crystalline complex. The temperature of the solution in step (b) is about the same as or lower than in step (a). During storage the temperature of the solution is preferably lowered, preferably to a temperature in the range of 20°C to 0°C or even lower. The step (b) can be carried out with or without stirring. As known to the one skilled in the art by the period of time and the difference of temperature in step (b) the size, shape and quality of the obtained crystals can be controlled. Furthermore the crystallization may be induced by methods as known in the art, for example by mechanical means such as scratching or rubbing the contact surface of the reaction vessel for example with a glass rod. Optionally the (nearly) saturated or supersaturated solution may be inoculated with seed crystals.

**[0134]** In step (c) the solvent(s) can be removed from the precipitate by known methods as for example filtration, suction filtration, decantation or centrifugation.

**[0135]** In step (d) an excess of the solvent(s) is removed from the precipitate by methods known to the one skilled in the art as for example by reducing the partial pressure of the solvent(s), preferably in vacuum, and/or by heating above ca. 20°C, preferably in a temperature range below 100°C, even more preferably below 85°C.

**[0136]** Compound A may be synthesized by methods as specifically and/or generally described or cited in international application WO2007/128749 and/or in the Examples disclosed herein below. Biological properties of the compound A may also be investigated as is described in WO2007/128749.

**[0137]** A crystalline complex as described herein is preferably employed as drug active substance in substantially pure form, that is to say, essentially free of other crystalline forms of the SGLT2 inhibitor (compound A). Nevertheless, the invention also embraces a crystalline complex in admixture with another crystalline form or forms. Should the drug active substance be a mixture of crystalline forms, it is preferred that the substance comprises at least 50%-weight, even more preferably at least 90%-weight, most preferably at least 95%-weight of the crystalline complex as described herein.

**[0138]** In view of its ability to inhibit SGLT activity, a crystalline complex according to the invention is suitable for the use in the treatment and/or preventive treatment of conditions or diseases which may be affected by the inhibition of SGLT activity, particularly SGLT-2 activity, in particular the metabolic disorders as described herein. The crystalline complex according to the invention is also suitable for the preparation of pharmaceutical compositions for the treatment and/or preventive treatment of conditions or diseases which may be affected by the inhibition of SGLT activity, particularly SGLT-2 activity, in particular metabolic disorders as described herein. A crystalline complex as described herein (in particular of compound A with a natural amino acid, e.g. proline, particularly L-proline) is also suitable for the use in the treatment of equine.

**Pharmaceutical compositions and formulations**

**[0139]** The SGLT2 inhibitor for use according to the invention as claimed may be prepared as pharmaceutical compositions. It may be prepared as solid or as liquid formulations. In either case, it is preferably prepared for oral administration, preferably in liquid form for oral administration. The SGLT2 inhibitor may, however, also be prepared, e.g., for parenteral administration.

**[0140]** Solid formulations include tablets, granular forms, and other solid forms such as suppositories. Among solid formulations, tablets and granular forms are preferred.

**[0141]** Pharmaceutical compositions within the meaning of the present invention may comprise the SGLT2 inhibitor according to the present invention as claimed and one or more excipients. Any excipient that allows for, or supports, the intended medical effect may be used. Such excipients are available to the skilled person. Useful excipients are for example antiadherents (used to reduce the adhesion between the powder (granules) and the punch faces and thus prevent sticking to tablet punches), binders (solution binders or dry binders that hold the ingredients together), coatings (to protect tablet ingredients from deterioration by moisture in the air and make large or unpleasant-tasting tablets easier to swallow), disintegrants (to allow the tablet to break upon dilution), fillers, diluents, flavours, colours, glidants (flow regulators - to promote powder flow by reducing interparticle friction and cohesion), lubricants (to prevent ingredients from clumping together and from sticking to the tablet punches or capsule filling machine), preservatives, sorbents, sweeteners etc.

**[0142]** Formulations according to the invention, e.g. solid formulations, may comprise carriers and/or disintegrants selected from the group of sugars and sugar alcohols, e.g. mannitol, lactose, starch, cellulose, microcrystalline cellulose and cellulose derivatives, e. g. methylcellulose, and the like.

**[0143]** Manufacturing procedures for formulations suitable for equine animals are known to the person skilled in the art, and for solid formulations comprise, e.g., direct compression, dry granulation and wet granulation. In the direct compression process, the active ingredient and all other excipients are placed together in a compression apparatus that is directly applied to press tablets out of this material. The resulting tablets can optionally be coated afterwards in order to protect them physically and/or chemically, e.g. by a material known from the state of the art.

**[0144]** A unit for administration, e.g. a single liquid dose or a unit of a solid formulation, e.g. a tablet, may comprise 5 to 2500 mg, or e.g. 5 to 2000 mg, 5 mg to 1500 mg, 10 mg to 1500 mg, 10 mg to 1000 mg, or 10-500 mg of the SGLT2 inhibitor as claimed for use according to the invention. As the skilled person would understand, the content of the SGLT2 inhibitor in a solid formulation, or any formulation as disclosed herein for administration to an equine animal, may be increased or decreased as appropriate in proportion to the body weight of the equine animal to be treated.

**[0145]** In one embodiment a pharmaceutical composition for use according to the invention is designed for oral or parenteral administration, preferably for oral administration. Especially the oral administration is ameliorated by excipients which modify the smell and/or haptic properties of the pharmaceutical composition for the intended patient, e.g. as described.

**[0146]** When the SGLT2 inhibitor as claimed for use according to the invention is formulated for oral administration, it is preferred that excipients confer properties, e.g. palatability and/or chewability that render the formulation suitable for administration to an equine animal.

**[0147]** Also preferred are liquid formulations. Liquid formulations may be, e.g., solutions, syrups or suspensions. They may be administered directly to the equine animal or may be mixed with the food and/or drink (e.g. drinking water, or the like) of the equine animal. One advantage of a liquid formulation (similar to a formulation in granular form), is that such a dosage form allows precise dosing. For example, the SGLT2 inhibitor may be dosed precisely in proportion to the body mass of an equine animal. Typical compositions of liquid formulations are known to the person skilled in the art. Apart from the active substance, liquid formulations may comprise e.g. solubilizing

**Dosing and administration**

**[0148]** A practitioner skilled in the art can determine suitable doses for the uses of the present invention. Preferred units dosing units include mg/kg, i.e. mg SGLT2 inhibitor per body mass of the equine animal. The SGLT2 inhibitor of the invention as claimed may, e.g., be administered in doses of 0.01-5 mg/kg bodyweight per day, e.g. 0.01-4 mg/kg, e.g. 0.01-3 mg/kg, e.g. 0.01-2 mg/kg, e.g. 0.01-1.5 mg/kg, e.g., 0.01-1 mg/kg, e.g. 0.01-0.75 mg/kg, e.g. 0.01-0.5 mg/kg, e.g. 0.01-0.4 mg/kg, e.g. 0.01-0.4 mg/kg bodyweight per day. Preferably the dose is 0.02-0.5 mg/kg bodyweight per day, more preferably 0.03-0.4 mg/kg bodyweight per day, e.g. 0.03-0.3 mg/kg bodyweight per day.

**[0149]** In a preferred embodiment, the SGLT2 inhibitor or a pharmaceutically acceptable form thereof may be administered in dosages of 0.01 to 3.0 mg/kg body weight per day, preferably from 0.02 to 1.0 mg/kg body weight per day, more preferably from 0.03 to 0.4 mg/kg body weight per day. Thus, the SGLT2 inhibitor or pharmaceutically acceptable form thereof may be prepared for the administration of 0.01 to 3.0 mg/kg body weight per day, preferably from 0.02 to 1.0 mg/kg body weight per day, more preferably from 0.03 to 0.4 mg/kg body weight per day.

**[0150]** A practitioner skilled in the art is able to prepare the SGLT2 inhibitor of the invention for administration according to a desired dose.

**[0151]** Preferably, according to the invention, the SGLT2 inhibitor is administered no more than three times per day, more preferably no more than twice per day, most preferably only once per day. The frequency of administration can be adapted to the typical feeding rate of the equine animal.

**[0152]** According to the invention, the SGLT2 inhibitor, i.e. compound A, may be administered such that an appropriate blood plasma concentration of the SGLT2 inhibitor is achieved (e.g. a maximal blood plasma concentration, or blood plasma concentration after a given time, e.g. 4, 8, 12 or 24 hours after oral administration, preferably about 8 hours after oral administration). E.g., for compound A, the blood plasma concentration (e.g. maximal blood plasma concentration or blood plasma concentration after said given time after oral administration) may be within the range 2 to 4000 nM, e.g. 20 to 3000 nM, or e.g. 40 to 2000 nM.

**[0153]** Preferably, following administration and the time required for the SGLT2 inhibitor to reach the bloodstream, such levels are maintained in the blood over a time interval of at least 12 hours, more preferably at least 18 hours, most preferably at least 24 h.

**[0154]** Preferably, according to the invention, the SGLT2 inhibitor as claimed is administered orally, in liquid or solid form. The SGLT2 inhibitor may be administered directly to the animals mouth (e.g. using a syringe, preferably a body-weight-graduated syringe) or together with the animal's food or drink (e.g. with its drinking water or the like), in each case preferably in liquid form. The SGLT2 inhibitors may, however, also be administered, e.g., parenterally, or by any other route of administration, e.g., rectally.

**[0155]** The SGLT2 inhibitor may be used alone or in combination with another drug. In some embodiments, the SGLT2 inhibitor is used in combination with one or more further oral antihyperglycaemic drugs. When the SGLT2 inhibitor is used in combination with a further drug, the SGLT2 inhibitor and any further drug may be administered simultaneously, sequentially (in any order), and/or according to a chronologically staggered dosage regime. In such embodiments, when a further drug for combined administration with the SGLT2 inhibitor is not administered simultaneously with the SGLT2 inhibitor, the SGLT2 inhibitor and any further drug are preferably administered within a period of at least 2 weeks, 1 month, 2 months, 4 months, 6 months or longer, e.g. 12 months or more.

**[0156]** In some embodiments the SGLT2 inhibitor (whether used alone or in combination with another drug) is not used in combination with 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(R)-amino-piperidin-1-yl]-xanthine or a pharmaceutically acceptable salt thereof, i.e. the equine animal is not treated with said compound. In some embodiments the SGLT2 inhibitor is not used in combination with a DPP-IV inhibitor, i.e., the equine animal is not treated with a DPP-IV inhibitor.

**[0157]** In some embodiments, the SGLT2 inhibitor is used as a monotherapy, i.e. stand-alone therapy, i.e. no other medication is administered to the equine animal for the treatment and/or prevention of the same metabolic disorder, i.e. the metabolic disorder for which the SGLT2 inhibitor is administered. E.g., no other medication is administered to the equine animal for the treatment and/or prevention of the same metabolic disorder within a period of at least 2, 3, or 4 weeks before and after administration of the SGLT2 inhibitor.

## BRIEF DESCRIPTION OF THE FIGURES

### **[0158]**

Figure 1 shows that doses of 0.3 mg/kg bodyweight or 3 mg/kg bodyweight orally, or 1 mg/kg bodyweight i.v. of compound A, all caused prominent increases of urinary glucose concentration in horses.

Figure 2 shows the correlation between compound A plasma level and urinary glucose excretion normalized to urinary creatinine (glucose/creatinine)

Figure 3 compares relative changes in blood glucose over a period of 0-210 minutes (mean values; baseline as covariate) in an oral sugar test (OST) in treated and control animals on day 28 of the treatment period (bold lines) with the same animals on day -14 before the beginning of the treatment period (dotted lines). For comparison the fine dotted lines depicts the time course of the glucose excursion in the OST of a healthy glucose tolerant horse.

Figure 4 shows the change of plasma glucose [mM] during a time courses after treatment with compound A or its vehicle and feeding. For the control group individual data are given, whereas for horses treated with compound A mean data are given for each dosing group (0.3 mg/kg bodyweight or 3 mg/kg bodyweight orally, or 1 mg/kg bodyweight i.v.).

Figure 5 shows a time course of blood insulin concentrations [ $\mu$ IU/mL] in insulin resistant horses during an OST after 4 weeks of treatment with compound A (solid lines) or its vehicle (dotted lines). Mean group values are given. Bold line: 2h after compound/vehicle administration; thinner line: 24h after last compound/vehicle administration.

- Figure 6 shows basal plasma insulin levels [mIU/mL] before treatment (day -12), on day 14 and on day 29 of treatment with compound A or its vehicle. Individual data (thin lines) and the group mean values (bold lines) are given.
- Figure 7 shows the basal insulin sensitivity of treated and control horses as expressed by the QUICKI (quantitative insulin sensitivity check index, i.e.  $1/(\log(\text{fasting insulin pmol/L}) + \log(\text{fasting glucose mmol/L}))$ ). Measurements were taken before treatment (day -12), on day 14 and on day 29 of treatment with compound A or its vehicle. Individual data (thin lines) and the group mean values (bold lines) are given.
- Figure 8 shows plasma insulin AUC (area under curve) values [mIU/mL/min] (baseline as covariate) before treatment (day -12), on day 28 (2 h after compound/vehicle administration) and on day 30 (24h after last compound/vehicle administration) of treatment with compound A or its vehicle. Individual data (thin lines) and the group mean values (bold lines) are given.
- Figure 9 shows the insulin sensitivity of treated and control horses as expressed by the Belfiore insulin sensitivity index (i.e.  $1/(\log(\text{AUC}\Delta\text{insulin} \times \text{AUC}\Delta\text{glucose}))$ ). Measurements were taken before treatment (day -12), on day 28 (2 h after compound/vehicle administration) and on day 30 (24h after last compound/vehicle administration) of treatment with compound A or its vehicle. Individual data (thin lines) and the group mean values (bold lines) are given.
- Figure 10 shows the time course of the elimination of non-esterified fatty acids (NEFAs,  $\mu\text{Eq/L}$ ) from the bloodstream as measured during an intravenous insulin tolerance test (ivITT). Mean group values are given of the horses treated with compound A (solid lines) or its vehicle (dotted lines). Panel A shows the results of the ivITT prior to the treatment periode, Panel B represent the results after 5 weeks of treatment.
- Figure 11 shows the basal plasma leptin levels [ng/mL] before treatment (day -12), on day 14 and on day 29 of treatment with compound A or its vehicle. Individual data (thin lines) and the group mean values (bold lines) are given.
- Figure 12 shows the horses body mass [kg] before treatment (day -12), on day 14 and on day 29 of treatment with compound A or its vehicle. Individual data (thin lines) and the group mean values (bold lines) are given.
- Figure 13 shows an X-ray powder diffraction pattern of a representative batch of a crystalline complex of compound A with L-proline (1:1)
- Figure 14 shows a DSC/TG diagram of a representative batch of a crystalline complex of compound A with L-proline (1:1)

### EXAMPLES

[0159] The following examples show the beneficial therapeutic effects on glycaemic control and/or insulin resistance, etc., of using of the SGLT2 inhibitor as claimed in equine animals, according to the present invention. These examples are intended to illustrate the invention in more detail without any limitation of the scope of the claims.

#### Example 1 Pharmacokinetics (PK)/ Pharmacodynamics (PD) of compound A single oral dosing in horses

[0160] Compound A was administered to overnight fasted horses. The groups (n=3 per group) received a single oral or intravenous (i.v.) administration of either vehicle alone (purified water, macrogol 15, hydroxystearate) or vehicle containing the SGLT2 inhibitor at a dose of 0.3 mg/kg bodyweight and 3 mg/kg bodyweight orally and 1 mg/kg bodyweight i.v.. PK/PD measurements were taken until day 3 after a single administration of compound A or its vehicle.

Table 2: Pharmacokinetic data, single dose

Parameter		1 mg/kg i.v.	0.3 mg/kg p.o.	3.0 mg/kg p.o.
t <sub>max</sub> [hour]	mean		2	1
C <sub>max</sub> [nmol/L]	mean		353	3867
AUC <sub>0→∞</sub> [nmol-h/1]	mean	41251	2869	29752
T <sub>1/2</sub> [hour]	mean	7.9	8.5	8.2

[0161] Pharmacodynamic data:

- A prominent increase of urinary glucose concentration was evident at all doses already 1h after administration (mean group values: controls 0.6 mmol/L; 1 mg/kg iv - 253 mmol/L; 0.3 mg/kgpo - 103 mmol/L; 3 mg/kg po - 217 mmol/L) and was persistent for more than 24 h (see Figure 1).
- None of the doses of compound A altered the basal blood glucose level in horses as compared to normal reference

values.

- None of the doses of compound A altered the renal function of horses.

[0162] Urinary glucose excretion increase is clearly plasma compound exposure dependent, as shown in Figure 2.

### Example 2 The effect of compound A on urinary and blood glucose as well as glucose tolerance after repeated dosing in horses

[0163] Compound A was administered to freely fed normoglycemic, hyperinsulinemic, insulin resistant, obese horses, which exhibit an impaired glucose tolerance. The groups (n=4 per group) received a once daily oral administration of either vehicle alone (purified water, macrogol 15, hydroxystearate - 0.2 mL/100 kg and approximately 35 mL of apple sauce) or vehicle containing the SGLT2 inhibitor in increasing doses up to 1 mg/kg for 4 weeks. The treated horses received a daily dose of compound A at 0.1 mg/kg bodyweight for the first 7 days, followed by 0.2 mg/kg bodyweight, from day 20 the dose was increased to 1 mg/kg bodyweight. Urinary glucose and blood glucose were measured. Additionally, to evaluate the glucose tolerance, blood glucose was measured during an oral sugar test (OST, corn syrup 0.15 mL/kg) was performed. Blood was collected via jugular vein catheters. Blood samples were taken prior and at 60, 90, 120, 150, 180, and 210 min relative to sugar application.

- The urinary glucose concentration was significantly elevated by the treatment - controls < 1 mmol/L; treated - ~ 300 mmol/L.
- Basal blood glucose levels remained within normal ranges in all horses throughout the study. No hypoglycaemia was observed.

[0164] Figure 3 shows blood glucose levels over a period of 0-210 minutes in an oral sugar test (OST) in animals treated with compound A and in control animals treated only with vehicle on day 28 of the treatment period. Mean values are shown (n=4 per group).

[0165] Comparison of the glucose curves at the end of the study revealed a statistical significant tendency (p=0.066) for a reduction of the glucose AUC in the horses treated with compound A. The plasma glucose concentration at 90 minutes after the challenge was significantly (p=0.038) lower in the treated horses.

[0166] These data indicate that treated horses experienced a significant improvement of their glucose tolerance.

### Example 3 The effect of compound A on postprandial blood glucose in horses

[0167] The following example shows the effect of compound A on postprandial blood glucose in horses. Compound A was administered to overnight fasted horses. The groups (n=3 per group) received a single oral or i.v. administration of either vehicle alone (purified water, macrogol 15, hydroxystearate) or vehicle containing the SGLT2 inhibitor at a dose of 0.3 mg/kg and 3 mg/kg orally and 1 mg/kg i.v.. Two hours after compound administration horses were fed a test meal. The postprandial glycemia is quantified 2 hours thereafter and significantly blunted by all doses of compound A, as shown in Figure 4. Compound A is thus clearly capable of effectively reducing postprandial glucose levels in horses.

[0168] The efficacy of SGLT2 inhibition in accordance with the invention in the treatment of pathological fasting glucose and/or insulin and/or impaired glucose tolerance can be tested using clinical studies. In studies over a shorter or longer period (e.g. 2-4 weeks or 1-2 years) the success of the treatment is examined by determining the fasting glucose and insulin values and/or the glucose values after a meal or after a loading test (oral glucose tolerance test or food tolerance test after a defined meal) after the end of the period of therapy for the study and comparing them with the values before the start of the study and/or with those of a placebo group. In addition, the fructosamine value can be determined before and after therapy and compared with the initial value and/or the placebo value. A significant drop in the fasting or non-fasting glucose and/or insulin and/or fructosamine levels demonstrates the efficacy of the treatment.

### Example 4 Effect upon insulin sensitivity and plasma insulin levels in horses

[0169] The following example shows the beneficial effect of compound A in insulin resistant obese horses. Compound A was administered to freely fed normoglycemic, obese horses. The groups (n=4 per group) received a once daily oral administration of either vehicle alone (purified water, macrogol 15, hydroxystearate - 0.2 mL/100 kg and approximately 35 mL of apple sauce) or vehicle containing the SGLT2 inhibitor in increasing doses up to 1 mg/kg bodyweight for 4 weeks. The following experiment was performed prior to treatment, and at the end of the 4 week treatment period. The treated horses received a daily dose of compound A at 0.1 mg/kg bodyweight for the first 7 days, followed by 0.2 mg/kg bodyweight, until day 20 from thereon until the end of the study the dose was increased to 1 mg/kg bodyweight. At days 28 and 30 the following experiment was performed twice, once approximately 2h and another time approximately 24h

after the last administration of compound A or its vehicle.

[0170] An oral sugar test (OST, corn syrup 0.15 mL/kg) was performed. Blood was collected via jugular vein catheters. Blood samples were taken prior and at 60, 90, 120, 150, 180, and 210 min relative to sugar application. Glucose and insulin excursions were quantified by calculating the baseline corrected glucose AUC.

[0171] The significance of differences of means between groups was evaluated by repeated-measures two-factor (time & treatment) ANOVA and post hoc multiple comparisons versus control or the respective baseline readings.

[0172] The baseline corrected glucose excursion during the OST did not change during the study period or by the treatment. The insulin excursion in control horses was not altered throughout the study period but was significantly reduced in treated horses as compared to pretreatment or control horses ( $p < 0.05$ , see Figure 8). Figure 5 shows a time course of blood insulin concentrations [ $\mu$  IU/mL] in the insulin resistant obese horses during an OST after 4 weeks of treatment with compound A or its vehicle.

[0173] Plasma insulin levels significantly decreased over the four-week treatment period in horses treated with compound A, but remained essentially unchanged on average in control horses given vehicle only (see Figure 6).

[0174] Insulin sensitivity was significantly increased in treated horses as compared to pretreatment values. This was demonstrated by determining basal insulin sensitivity values as expressed by the QUICKY index ( $1/\log(\text{gluc} \cdot \text{ins})$ ) and during the challenge (OST) by the modified Belfiore index ( $1/\log(\Delta\text{AUC gluc} \cdot \Delta\text{AUC ins})$ ). As shown in Figure 7 and in Figure 9, in the course of the four-week treatment period, insulin sensitivity significantly increased in treated horses, but remained essentially unchanged in control horses given vehicle only.

[0175] These data indicate that the insulin resistance was significantly improved after a 2 to 4 week treatment with compound A.

#### Example 5 Effect upon dyslipidemia, dysadipokinemia and body weight/obesitas in horses

[0176] The following example shows the beneficial effect of compound A in insulin resistant obese horses. The details of the experiments are described in example 4.

[0177] To test the effect of compound A treatment on blood lipid handling/elimination an intravenous insulin tolerance test (ivITT, 0.03 U insulin per kg body mass) was performed prior to start of and on day 35 of the treatment period. The test was performed prior to the morning feeding and approximately 24h after the last administration of compound A or its vehicle (day 35 only). Blood was collected prior to and at 15, 30, 60, 90, 120 and 150 minutes after the insulin challenge. Figure 5 shows a time course of baseline corrected blood NEFA concentrations [ $\mu$ Eq/L] in the insulin resistant obese horses during an ivITT.

[0178] The baseline corrected NEFA elimination curve during the ITT was clearly not different between the groups prior to treatment (see Figure 10, panel A). At the end of the treatment period NEFA elimination was significantly improved by the compound A treatment (see Figure 10, panel B).

[0179] The use of an SGLT2 inhibitor according to the present invention advantageously also reduced blood leptin levels. As shown in Figure 11, in the course of the four-week treatment period, plasma leptin concentrations significantly decreased in treated horses, but remained essentially unchanged in control horses given vehicle only.

[0180] Additionally, the use of an SGLT2 inhibitor according to the present invention also reduced significantly the body weight of obese horses treated with compound A (see Figure 12) in the course of the four-week treatment period.

[0181] These data indicate that after a 2 to 5 week treatment with compound A obese, insulin resistant horses showed significantly improved handling of blood lipids (elimination after a challenge) and an improved adipokine profile with reduced blood leptin concentrations. Additionally, the body weight was significantly reduced by treatment with compound A and indicates the potential to influence obesity and/ or regional adiposity in horses.

[0182] The efficacy of SGLT2 inhibition in accordance with the invention in the treatment of pathological obesity and/ or regional adiposity can be tested using clinical studies. In studies over a shorter or longer period (e.g. 3-6 months or 1-2 years) the success of the treatment is examined by determining e.g. body weight, body condition scores, other morphometric measurements or non-invasive body composition determination methods, e.g. ultrasound determination of fat pad dimension or deuterium oxide dilution (heavy water) methods. A significant difference in these values during or at the end of the study, compared with the initial value or compared with a placebo group, or a group given a different therapy, proves the efficacy of a pharmaceutical composition according to the invention in the reduction of obesitas and/ or regional adipositas.

#### Example 6 Effects on parameters of inflammation

[0183] In clinical studies in horses with metabolic disorders according to the present invention running for different lengths of time (e.g. 2 weeks to 12 months) the effect of the treatment with SGLT2 inhibitors according to the invention on inflammation (be it subclinical inflammation, systemic inflammation, low grade systemic inflammation) is evaluated by determining in the blood stream for example the concentration of proinflammatory cytokines (e.g. TNF-alpha or IL-

6) or acute phase proteins (e.g. serum amyloid A or haptoglobin). A significant fall in these values during or at the end of the study, compared with the initial value or compared with a placebo group, or a group given a different therapy, proves the efficacy of a pharmaceutical composition according to the invention in the reduction of parameters of inflammation in horses with metabolic disorders.


#### Example 7 Preparation of 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzene (compound A)

[0184] In the foregoing and following text, H atoms of hydroxyl groups are not explicitly shown in every case in structural formulae. The following example of synthesis serves to illustrate a method of preparing 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzene (compound A). A method of preparing its crystalline complex with L-proline is also described. It is to be regarded only as a possible method described by way of example, without restriction of the scope of the invention. The terms "room temperature" and "ambient temperature" are used interchangeably and denote temperatures of about 20°C. The following abbreviations are used:

DMF dimethylformamide  
NMP N-methyl-2-pyrrolidone  
THF tetrahydrofuran

#### Preparation of 4-bromo-3-hydroxymethyl-1-iodo-benzene

[0185]




[0186] Oxalyl chloride (13.0 mL) is added to an ice-cold solution of 2-bromo-5-iodo-benzoic acid (49.5 g) in  $\text{CH}_2\text{Cl}_2$  (200 mL). DMF (0.2 mL) is added and the solution is stirred at room temperature for 6 h. Then, the solution is concentrated under reduced pressure and the residue is dissolved in THF (100 mL). The resulting solution is cooled in an ice-bath and  $\text{LiBH}_4$  (3.4 g) is added in portions. The cooling bath is removed and the mixture is stirred at room temperature for 1 h. The reaction mixture is diluted with THF and treated with 0.1 M hydrochloric acid. Then, the organic layer is separated and the aqueous layer is extracted with ethyl acetate. The combined organic layers are dried ( $\text{Na}_2\text{SO}_4$ ) and the solvent is evaporated under reduced pressure to give the crude product.

Yield: 47.0 g (99% of theory)

#### Preparation of 4-bromo-3-chloromethyl-1-iodo-benzene


[0187]



[0188] Thionyl chloride (13 mL) is added to a suspension of 4-bromo-3-hydroxymethyl-1-iodo-benzene (47.0 g) in dichloromethane (100 mL) containing DMF (0.1 mL). The mixture is stirred at ambient temperature for 3 h. Then, the solvent and the excess reagent is removed under reduced pressure. The residue is triturated with methanol and dried. Yield: 41.0 g (82% of theory)

## Preparation of 4-bromo-1-iodo-3-phenoxyethyl-benzene


[0189]



[0190] Phenol (13 g) dissolved in 4 M KOH solution (60 mL) is added to 4-bromo-3-chloromethyl-1-iodo-benzene (41.0 g) dissolved in acetone (50 mL). NaI (0.5 g) is added and the resulting mixture is stirred at 50 °C overnight. Then, water is added and the resulting mixture is extracted with ethyl acetate. The combined extracts are dried (Na<sub>2</sub>SO<sub>4</sub>) and the solvent is evaporated under reduced pressure. The residue is purified by chromatography on silica gel (cyclohexane/ethyl acetate 19:1).

Yield: 38.0 g (79% of theory)

## [0191] Preparation of 1-bromo-4-(1-methoxy-D-glucopyranos-1-yl)-2-(phenoxyethyl)-benzene




[0192] A 2 M solution of iPrMgCl in THF (11 mL) is added to dry LiCl (0.47 g) suspended in THF (11 mL). The mixture is stirred at room temperature until all the LiCl is dissolved. This solution is added dropwise to a solution of 4-bromo-1-iodo-3-phenoxyethyl-benzene (8.0 g) in tetrahydrofuran (40 mL) cooled to -60 °C under argon atmosphere. The solution is warmed to -40 °C and then 2,3,4,6-tetrakis-O-(trimethylsilyl)-D-glucopyranone (10.7 g, 90% pure) in tetrahydrofuran (5 mL) is added. The resulting solution is warmed to -5 °C in the cooling bath and stirred for another 30 min at this temperature. Aqueous NH<sub>4</sub>Cl solution is added and the resultant mixture is extracted with ethyl acetate. The combined organic extracts are dried over sodium sulfate and the solvent is removed under reduced pressure. The residue is dissolved in methanol (80 mL) and treated with methanesulfonic acid (0.6 mL) to produce the more stable anomer solely. After stirring the reaction solution at 35-40 °C overnight, the solution is neutralized with solid NaHCO<sub>3</sub> and the methanol is removed under reduced pressure. The remainder is diluted with aqueous NaHCO<sub>3</sub> solution and the resulting mixture is extracted with ethyl acetate. The combined extracts are dried over sodium sulfate and the solvent is evaporated to yield the crude product that is submitted to reduction without further purification.

Yield: 7.8 g (93% of theory)

## Preparation of 1-bromo-4-(2,3,4,6-tetra-O-acetyl-D-glucopyranos-1-yl)-2-(phenoxyethyl)-benzene

[0193]




**[0194]** Boron trifluoride diethyletherate (4.9 mL) is added to a solution of 1-bromo-4-(1-methoxy-D-glucopyranos-1-yl)-2-(phenoxy-methyl)-benzene (8.7 g) and triethylsilane (9.1 mL) in dichloromethane (35 mL) and acetonitrile (50 mL) cooled to -20 °C at such a rate that the temperature maintains below -10 °C. The resultant solution is warmed to 0 °C over a period of 1.5 h and then treated with aqueous sodium hydrogen carbonate solution. The resulting mixture is stirred for 0.5 h, the organic solvent is removed and the residue is extracted with ethyl acetate. The combined organic layers are dried over sodium sulfate and the solvent is removed. The residue is taken up in dichloromethane (50 mL) and pyridine (9.4 mL), acetic anhydride (9.3 mL) and 4-dimethylaminopyridine (0.5 g) are added in succession to the solution. The solution is stirred for 1.5 h at ambient temperature and then diluted with dichloromethane. This solution is washed twice with 1 M hydrochloric acid and dried over sodium sulfate. After the solvent is removed, the residue is recrystallized from ethanol to furnish the product as a colorless solid.

Yield: 6.78 g (60% of theory)

Mass spectrum (ESI<sup>+</sup>): m/z = 610/612 (Br) [M+NH<sub>4</sub>]<sup>+</sup>

#### Preparation of 2-(phenoxy-methyl)-4-(2,3,4,6-tetra-O-acetyl-D-glucopyranos-1-yl)-benzonitrile

**[0195]**



**[0196]** A flask charged with zinc cyanide (1.0 g), zinc (30 mg), Pd<sub>2</sub>(dibenzylideneacetone)<sub>3</sub>\*CHCl<sub>3</sub> (141 mg) and tritert-butylphosphonium tetrafluoroborate (111 mg) is flushed with argon. Then a solution of 1-bromo-4-(2,3,4,6-tetra-O-acetyl-D-glucopyranos-1-yl)-2-(phenoxy-methyl)-benzene (5.4 g) in NMP (12 mL) is added and the resulting mixture is stirred at room temperature for 18 h. After dilution with ethyl acetate, the mixture is filtered and the filtrate is washed with aqueous sodium hydrogen carbonate solution. The organic phase is dried (sodium sulfate) and the solvent is removed. The residue is recrystallized from ethanol.


Yield: 4.10 g (84% of theory)

Mass spectrum (ESI<sup>+</sup>): m/z = 557 [M+NH<sub>4</sub>]<sup>+</sup>

**[0197]** Alternatively, the compound described above is synthesized starting from 1-bromo-4-(2,3,4,6-tetra-O-acetyl-D-glucopyranos-1-yl)-2-(phenoxy-methyl)-benzene using copper(I) cyanide (2 equivalents) in NMP at 210 °C.

#### Preparation of 2-bromomethyl-4-(2,3,4,6-tetra-O-acetyl-D-glucopyranos-1-yl)-benzonitrile

**[0198]**




**[0199]** A 33% solution of hydrobromic acid in acetic acid (15 mL) is added to a solution of 2-phenyloxymethyl-4-(2,3,4,6-tetra-O-acetyl-D-glucopyranos-1-yl)-benzonitrile (0.71 g) and acetic anhydride (0.12 mL) in acetic acid (10 ml). The resulting solution is stirred at 55 °C for 6 h and then cooled in an ice-bath. The reaction mixture is neutralized with chilled aqueous potassium carbonate solution, and the resultant mixture is extracted with ethyl acetate. The combined organic extracts are dried over sodium sulfate and the solvent is removed under reduced pressure. The residue is taken up in ethyl acetate/cyclohexane (1:5), and the precipitate is separated by filtration and dried at 50 °C to give the pure product.

Yield: 0.52 g (75% of theory)

Mass spectrum (ESI<sup>+</sup>): m/z = 543/545 (Br) [M+NH<sub>4</sub>]<sup>+</sup>

#### Preparation of 4-cyclopropyl-phenylboronic acid

**[0200]**




**[0201]** 2.5 M solution of nButyllithium in hexane (14.5 mL) is added dropwise to 1-bromo-4-cyclopropyl-benzene (5.92 g) dissolved in THF (14 mL) and toluene (50 mL) and chilled to -70 °C. The resultant solution is stirred at -70 °C for 30 min before triisopropyl borate (8.5 mL) is added. The solution is warmed to -20 °C and then treated with 4 M aqueous hydrochloric acid (15.5 mL). The reaction mixture is further warmed to room temperature and then the organic phase is separated. The aqueous phase is extracted with ethyl acetate and the combined organic phases are dried (sodium sulfate). The solvent is evaporated and the residue is washed with a mixture of ether and cyclohexane to give the product as a colorless solid.

Yield: 2.92 g (60% of theory)

Mass spectrum (ESI<sup>-</sup>): m/z = 207 (Cl) [M+HCOO]<sup>-</sup>

#### Preparation of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene

**[0202]**



## EP 2 981 269 B9

[0203] An Ar filled flask is charged with 2-bromomethyl-4-(2,3,4,6-tetra-O-acetyl-D-glucopyranos-1-yl)-benzotrile (1.60 g), 4-cyclopropyl-phenylboronic acid (1.0 g), potassium carbonate (1.85 g) and a degassed 3:1 mixture of acetone and water (22 mL). The mixture is stirred at room temperature for 5 min, before it is cooled in an ice-bath. Then palladium dichloride (30 mg) is added and the reaction mixture is stirred for 16 h at ambient temperature. The mixture is then diluted with brine and extracted with ethyl acetate. The combined extracts are dried over sodium sulfate and the solvent is removed under reduced pressure. The residue is dissolved in methanol (20 mL) and treated with 4 M aqueous potassium hydroxide solution (4 mL). The resulting solution is stirred at ambient temperature for 1 h and then neutralized with 1 M hydrochloric acid. The methanol is evaporated, and the residue is diluted with brine and extracted with ethyl acetate. The organic extracts collected are dried over sodium sulfate, and the solvent is removed. The residue is chromatographed on silica gel (dichloromethane/methanol 1:0 -> 8:1).

Yield: 0.91 g (76% of theory)

Mass spectrum (ESI<sup>+</sup>): m/z = 413 [M+NH<sub>4</sub>]<sup>+</sup>

### Preparation of a crystalline complex (1 : 1) of compound A with L-proline

[0204] L-proline (0.34 g) dissolved in 2.1 mL of a mixture of ethanol and water (volume ratio 10:1) is added to a solution of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene (1.17 g, obtained as described above) dissolved in 2 mL ethanol. The resulting solution is allowed to stand at ambient temperature. After about 16 h the crystalline complex is isolated as white crystals by filtration. If necessary the crystallisation may be initiated by scratching with a glass rod or metal spatula for example or by inoculating with seed crystals. Residual solvent is removed by storing the crystals at slightly elevated temperature (30 to 50 °C) under vacuum for about 4 h to yield 1.27 g of the crystalline 1:1 complex of L-proline and 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene.

[0205] Several batches of the crystalline complex according to the above preparation are obtained. The X-ray powder diffraction patterns coincide. The melting points are determined via DSC and evaluated as onset-temperature. Examples of melting points are approximately 89°C, 90°C, 92°C, 101 °C and 110°C. The X-ray powder diffraction pattern as contained in Table 2 and as depicted in Figure 13 and the DSC and TG diagram in Figure 14 correspond to a batch with a melting point of approximately 90°C.

[0206] The X-ray powder diffraction pattern of the crystalline complex of the compound A and L-proline (peaks up to 30° in 2 θ) is provided above in Table 1.

### Example 8 Formulations

[0207] Some examples of formulations are described in which the term "active substance" denotes an SGLT2 inhibitor or pharmaceutically acceptable form thereof, e.g. a prodrug or a crystalline form, for use according to the invention. In the case of a combination with one or additional active substances, the term "active substance" may also include the additional active substance.

#### Tablets containing 100 mg of active substance

Composition:

[0208] 1 tablet contains:

active substance	100.0 mg
lactose	80.0 mg
corn starch	34.0 mg
polyvinylpyrrolidone	4.0 mg
magnesium stearate	2.0 mg
	<hr/>
	220.0 mg

Method of Preparation:

[0209] The active substance, lactose and starch are mixed together and uniformly moistened with an aqueous solution of the polyvinylpyrrolidone. After the moist composition has been screened (2.0 mm mesh size) and dried in a rack-type drier at 50°C it is screened again (1.5 mm mesh size) and the lubricant is added. The finished mixture is compressed

## EP 2 981 269 B9

to form tablets.

Weight of tablet: 220 mg

Diameter: 10 mm, biplanar, faceted on both sides and notched on one side.

5

### Tablets containing 150 mg of active substance

Composition:

10 [0210] 1 tablet contains:

	active substance	150.0 mg
	powdered lactose	89.0 mg
	corn starch	40.0 mg
15	colloidal silica	10.0 mg
	polyvinylpyrrolidone	10.0 mg
	magnesium stearate	1.0 mg
		<hr/>
		300.0 mg

20

Preparation:

25 [0211] The active substance mixed with lactose, corn starch and silica is moistened with a 20% aqueous polyvinylpyrrolidone solution and passed through a screen with a mesh size of 1.5 mm. The granules, dried at 45°C, are passed through the same screen again and mixed with the specified amount of magnesium stearate. Tablets are pressed from the mixture.

25

Weight of tablet: 300 mg

die: 10 mm, flat

30

### Hard gelatine capsules containing 150 mg of active substance

Composition:

35 [0212] 1 capsule contains:

	active substance	150.0 mg
	corn starch (dried)	approx. 180.0 mg
	lactose (powdered)	approx. 87.0 mg
40	magnesium stearate	3.0 mg
		<hr/>
		approx. 420.0 mg

40

45 Preparation:

[0213] The active substance is mixed with the excipients, passed through a screen with a mesh size of 0.75 mm and homogeneously mixed using a suitable apparatus. The finished mixture is packed into size 1 hard gelatine capsules.

50

Capsule filling: approx. 320 mg

Capsule shell: size 1 hard gelatine capsule.

### Suppositories containing 150 mg of active substance

55 Composition:

[0214] 1 suppository contains:

## EP 2 981 269 B9

5	active substance	150.0 mg
	polyethyleneglycol 1500	550.0 mg
	polyethyleneglycol 6000	460.0 mg
	polyoxyethylene sorbitan monostearate	840.0 mg
		<hr/>
		2,000.0 mg

10 Preparation:

**[0215]** After the suppository mass has been melted the active substance is homogeneously distributed therein and the melt is poured into chilled moulds.

### 15 Ampoules containing 10 mg active substance

Composition:

#### 20 [0216]

20	active substance	10.0 mg
	0.01 N hydrochloric acid / NaCl	q.s.
	double-distilled water	ad 2.0 ml

25 Preparation:

**[0217]** The active substance is dissolved in the necessary amount of 0.01 N HCl, made isotonic with common salt, filtered sterile and transferred into 2 ml ampoules.

### 30 Ampoules containing 50 mg of active substance

Composition:

#### 35 [0218]

35	active substance	50.0 mg
	0.01 N hydrochloric acid / NaCl	q.s.
	double-distilled water	ad 10.0 ml

40 Preparation:

**[0219]** The active substance is dissolved in the necessary amount of 0.01 N HCl, made isotonic with common salt, filtered sterile and transferred into 10 ml ampoules.

## 45 REFERENCES


### [0220]

- 50 1) Frank et al. (2010) Journal of Veterinary Internal Medicine 24(3):467-75  
2) WO01/27128  
3) WO03/099836  
4) WO2005/092877  
5) WO2006/034489  
55 6) WO2006/064033  
7) WO2006/117359  
8) WO2006/117360  
9) WO2007/025943

- 10) WO2007/028814  
 11) WO2007/031548  
 12) WO2007/093610  
 13) WO2007/128749  
 5 14) WO2008/049923  
 15) WO2008/055870  
 16) WO2008/055940  
 17) WO2009/022020  
 18) WO2009/022008  
 10 19) WO2008/116179  
 20) WO2008/002824  
 21) WO2005/012326  
 22) WO2009/035969  
 23) WO2008/069327  
 15 24) WO2006/120208  
 25) WO2011/039108  
 26) WO2011/039107  
 27) WO2004/007517  
 28) WO2004/080990  
 20 29) WO2007/114475  
 30) WO2007/140191  
 31) WO2008/013280  
 32) WO2010/023594  
 33) EP1213296  
 25 34) EP1354888  
 35) EP1344780  
 36) EP1489089  
 37) WO2008/042688  
 38) WO2009/014970  
 30 39) WO2014/016381

### Claims

- 35 1. An SGLT2 inhibitor or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal, wherein said SGLT2 inhibitor is 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzene, represented by formula (2):




- 50 2. The SGLT2 inhibitor or a pharmaceutically acceptable form thereof for a use according to claim 1, wherein the metabolic disorder is one or more disorders selected from insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, and/or regional adiposity, wherein preferably the metabolic disorder is insulin resistance, hyperinsulinemia, and/or a clinical condition associated with insulin resistance and/or hyperinsulinaemia.
- 55 3. The SGLT2 inhibitor or pharmaceutically acceptable form thereof for a use according to claim 2, wherein said clinical condition is one or more conditions selected from impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, and/or regional adiposity.

4. The SGLT2 inhibitor or pharmaceutically acceptable form thereof for a use according to any one of claims 1 to 3, wherein the equine animal is suffering from one or more of impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, which also comprises adipose tissue, obesity, and/or regional adiposity.
5. The SGLT2 inhibitor or pharmaceutically acceptable form thereof for a use according to claim 2 to 4, wherein said impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, and/or regional adiposity is associated with insulin resistance and/or hyperinsulinemia.
6. The SGLT2 inhibitor or pharmaceutically acceptable form thereof for a use according to claim 1 to 4, wherein the metabolic disorder is hyperinsulinemia and/or insulin resistance, wherein said hyperinsulinemia or insulin resistance is optionally associated with one or more of impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, which also comprises adipose tissue, obesity, and/or regional adiposity.
7. The SGLT2 inhibitor or pharmaceutically acceptable form thereof for a use according to any one of claims 1 to 6, wherein the equine animal is a horse or a pony.
8. The SGLT2 inhibitor or pharmaceutically acceptable form thereof for a use according to any one of claims 1 to 7, wherein the equine animal is obese and/or exhibits regional adiposity.
9. The SGLT2 inhibitor or pharmaceutically acceptable form thereof for a use according to any one of claims 1 to 8, wherein the pharmaceutically acceptable form is a crystalline complex between the SGLT2 inhibitor and one or more amino acids, preferably wherein the one or more amino acids is proline.
10. The SGLT2 inhibitor or pharmaceutically acceptable form thereof for a use according to any one of claims 1 to 9 for oral or parenteral administration, preferably for oral administration.
11. The SGLT2 inhibitor or a pharmaceutically acceptable form thereof for a use according to any one of claims 1 to 10, for the administration of 0.01 to 5 mg/kg body weight per day, preferably from 0.01 to 4 mg/kg body weight per day, more preferably from 0.01 to 3.0 mg/kg body weight per day, even more preferably from 0.02 to 1.0 mg/kg body weight per day, most preferably from 0.03 to 0.4 mg/kg body weight per day.
12. The SGLT2 inhibitor or pharmaceutically acceptable form thereof for a use according to any one of claims 1 to 11, wherein such SGLT2 inhibitor or pharmaceutically acceptable form is to be administered only once per day.
13. A pharmaceutical composition comprising the SGLT2 inhibitor of any one of claims 1 to 12 or a pharmaceutically acceptable form thereof for a use according to any one of claims 1 to 12.

### Patentansprüche

1. SGLT2-Inhibitor oder eine pharmazeutisch verträgliche Form davon zur Verwendung bei der Behandlung und/oder Vorbeugung einer Stoffwechselstörung eines pferdeartigen Tieres, wobei der SGLT2-Inhibitor 1-Cyano-2-(4-cyclopropyl-benzyl)-4-((β-D-glucopyranos-1-yl)-benzol ist, dargestellt durch die Formel (2):




2. SGLT2-Inhibitor oder eine pharmazeutisch verträgliche Form davon für eine Verwendung nach Anspruch 1, wobei

die Stoffwechselstörung eine oder mehrere Störungen ausgewählt aus Insulinresistenz, Hyperinsulinämie, gestörter Glukosetoleranz, Dyslipidämie, Dysadipokinämie, subklinischer Entzündung, systemischer Entzündung, niedriggradiger systemischer Entzündung, Obesität und/oder lokaler Adipositas ist, wobei die Stoffwechselstörung bevorzugt Insulinresistenz, Hyperinsulinämie und/oder ein mit Insulinresistenz und/oder Hyperinsulinämie assoziierter klinischer Zustand ist.

3. SGLT2-Inhibitor oder pharmazeutisch verträgliche Form davon für eine Verwendung nach Anspruch 2, wobei der klinische Zustand ein oder mehrere Zustände ausgewählt aus gestörter Glukosetoleranz, Dyslipidämie, Dysadipokinämie, subklinischer Entzündung, systemischer Entzündung, niedriggradiger systemischer Entzündung, Obesität und/oder lokaler Adipositas ist.
4. SGLT2-Inhibitor oder pharmazeutisch verträgliche Form davon für eine Verwendung nach einem der Ansprüche 1 bis 3, wobei das pferdeartige Tier an einer oder mehreren von gestörter Glukosetoleranz, Dyslipidämie, Dysadipokinämie, subklinischer Entzündung, systemischer Entzündung, niedriggradiger systemischer Entzündung, was auch Fettgewebe, Obesität und/oder lokale Adipositas umfasst, leidet.
5. SGLT2-Inhibitor oder pharmazeutisch verträgliche Form davon für eine Verwendung nach den Ansprüchen 2 bis 4, wobei die gestörte Glukosetoleranz, Dyslipidämie, Dysadipokinämie, subklinische Entzündung, systemische Entzündung, niedriggradige systemische Entzündung, Obesität und/oder lokale Adipositas mit Insulinresistenz und/oder Hyperinsulinämie assoziiert ist.
6. SGLT2-Inhibitor oder pharmazeutisch verträgliche Form davon für eine Verwendung nach den Ansprüchen 1 bis 4, wobei die Stoffwechselstörung Hyperinsulinämie und/oder Insulinresistenz ist, wobei die Hyperinsulinämie oder Insulinresistenz gegebenenfalls mit einer oder mehreren von gestörter Glukosetoleranz, Dyslipidämie, Dysadipokinämie, subklinischer Entzündung, systemischer Entzündung, niedriggradiger systemischer Entzündung, was auch Fettgewebe, Obesität und/oder lokale Adipositas umfasst, assoziiert ist.
7. SGLT2-Inhibitor oder pharmazeutisch verträgliche Form davon für eine Verwendung nach einem der Ansprüche 1 bis 6, wobei das pferdeartige Tier ein Pferd oder ein Pony ist.
8. SGLT2-Inhibitor oder pharmazeutisch verträgliche Form davon für eine Verwendung nach einem der Ansprüche 1 bis 7, wobei das pferdeartige Tier adipös ist und/oder lokale Adipositas zeigt.
9. SGLT2-Inhibitor oder pharmazeutisch verträgliche Form davon für eine Verwendung nach einem der Ansprüche 1 bis 8, wobei die pharmazeutisch verträgliche Form ein kristalliner Komplex zwischen dem SGLT2-Inhibitor und einer oder mehreren Aminosäuren ist, wobei die eine oder mehreren Aminosäuren bevorzugt Prolin ist.
10. SGLT2-Inhibitor oder pharmazeutisch verträgliche Form davon für eine Verwendung nach einem der Ansprüche 1 bis 9 zur oralen oder parenteralen Verabreichung, bevorzugt zur oralen Verabreichung.
11. SGLT2-Inhibitor oder pharmazeutisch verträgliche Form davon für eine Verwendung nach einem der Ansprüche 1 bis 10 zur Verabreichung von 0,01 bis 5 mg/kg Körpergewicht pro Tag, bevorzugt von 0,01 bis 4 mg/kg Körpergewicht pro Tag, bevorzugter von 0,01 bis 3,0 mg/kg Körpergewicht pro Tag, noch bevorzugter von 0,02 bis 1,0 mg/kg Körpergewicht pro Tag, am meisten bevorzugt von 0,03 bis 0,4 mg/kg Körpergewicht pro Tag.
12. SGLT2-Inhibitor oder pharmazeutisch verträgliche Form davon für eine Verwendung nach einem der Ansprüche 1 bis 11, wobei dieser SGLT2-Inhibitor oder diese pharmazeutisch verträgliche Form davon nur einmal pro Tag zu verabreichen ist.
13. Pharmazeutische Zusammensetzung, umfassend den SGLT2-Inhibitor nach einem der Ansprüche 1 bis 12 oder eine pharmazeutisch verträgliche Form davon für eine Verwendung nach einem der Ansprüche 1 bis 12.

#### Revendications

1. Inhibiteur de SGLT2 ou forme pharmaceutiquement acceptable de celui-ci pour son utilisation dans le traitement et/ou la prévention d'un trouble métabolique chez un équidé, dans lequel ledit inhibiteur de SGLT2 est le 1-cyano-2-(4-cyclopropyl-benzyl)-4-((β-D-glucopyranos-1-yl)-benzène, représenté par la formule (2) :



(2).

- 5
- 10
- 15
- 20
- 25
- 30
- 35
- 40
- 45
- 50
- 55
2. Inhibiteur de SGLT2 ou forme pharmaceutiquement acceptable de celui-ci pour son utilisation selon la revendication 1, dans lequel le trouble métabolique est un ou plusieurs troubles sélectionnés parmi une résistance à l'insuline, une hyperinsulinémie, une intolérance au glucose, une dyslipidémie, une dysadipocinémie, une inflammation sub-clinique, une inflammation systémique, une inflammation systémique de bas grade, une obésité, et/ou une adiposité régionale, dans lequel de préférence le trouble métabolique est une résistance à l'insuline, une hyperinsulinémie, et/ou une affection clinique associée à une résistance à l'insuline et/ou une hyperinsulinémie.
  3. Inhibiteur de SGLT2 ou forme pharmaceutiquement acceptable de celui-ci pour son utilisation selon la revendication 2, dans lequel ladite affection clinique est une ou plusieurs affections sélectionnées parmi une intolérance au glucose, une dyslipidémie, une dysadipocinémie, une inflammation subclinique, une inflammation systémique, une inflammation systémique de bas grade, une obésité, et/ou une adiposité régionale.
  4. Inhibiteur de SGLT2 ou forme pharmaceutiquement acceptable de celui-ci pour son utilisation selon l'une quelconque des revendications 1 à 3, dans lequel l'équidé souffre d'une ou plusieurs d'une intolérance au glucose, d'une dyslipidémie, d'une dysadipocinémie, d'une inflammation subclinique, d'une inflammation systémique, d'une inflammation systémique de bas grade, d'une obésité, et/ou d'une adiposité régionale.
  5. Inhibiteur de SGLT2 ou forme pharmaceutiquement acceptable de celui-ci pour son utilisation selon les revendications 2 à 4, dans lequel lesdites intolérance au glucose, dyslipidémie, dysadipocinémie, inflammation subclinique, inflammation systémique, inflammation systémique de bas grade, obésité, et/ou adiposité régionale sont associées à une résistance à l'insuline et/ou une hyperinsulinémie.
  6. Inhibiteur de SGLT2 ou forme pharmaceutiquement acceptable de celui-ci pour son utilisation selon les revendications 1 à 4, dans lequel le trouble métabolique est l'hyperinsulinémie et/ou la résistance à l'insuline, dans lequel ladite hyperinsulinémie ou résistance à l'insuline est éventuellement associée à une ou plusieurs d'une intolérance au glucose, d'une dyslipidémie, d'une dysadipocinémie, d'une inflammation subclinique, d'une inflammation systémique, d'une inflammation systémique de bas grade, qui comprend également le tissu adipeux, d'une obésité, et/ou d'une adiposité régionale.
  7. Inhibiteur de SGLT2 ou forme pharmaceutiquement acceptable de celui-ci pour son utilisation selon l'une quelconque des revendications 1 à 6, dans lequel l'équidé est un cheval ou un poney.
  8. Inhibiteur de SGLT2 ou forme pharmaceutiquement acceptable de celui-ci pour son utilisation selon l'une quelconque des revendications 1 à 7, dans lequel l'équidé est obèse et/ou présente une adiposité régionale.
  9. Inhibiteur de SGLT2 ou forme pharmaceutiquement acceptable de celui-ci pour son utilisation selon l'une quelconque des revendications 1 à 8, dans lequel la forme pharmaceutiquement acceptable est un complexe cristallin entre l'inhibiteur de SGLT2 et un ou plusieurs acides aminés, de préférence dans lequel les un ou plusieurs acides aminés sont la proline.
  10. Inhibiteur de SGLT2 ou forme pharmaceutiquement acceptable de celui-ci pour son utilisation selon l'une quelconque des revendications 1 à 9 pour une administration orale ou parentérale, de préférence pour une administration orale.
  11. Inhibiteur de SGLT2 ou forme pharmaceutiquement acceptable de celui-ci pour son utilisation selon l'une quelconque des revendications 1 à 10, pour l'administration de 0,01 à 5 mg/kg de poids corporel par jour, de préférence de 0,01 à 4 mg/kg de poids corporel par jour, de manière davantage préférée de 0,01 à 3,0 mg/kg de poids corporel par jour, de manière encore davantage préférée 0,02 à 1,0 mg/kg de poids corporel par jour, de manière préférée entre

toutes de 0,03 à 0,4 mg/kg de poids corporel par jour.

5 **12.** Inhibiteur de SGLT2 ou forme pharmaceutiquement acceptable de celui-ci pour son utilisation selon l'une quelconque des revendications 1 à 11, dans lequel un tel inhibiteur de SGLT2 ou une telle forme pharmaceutiquement acceptable est destiné à être administré une seule fois par jour.

10 **13.** Composition pharmaceutique comprenant l'inhibiteur de SGLT2 selon l'une quelconque des revendications 1 à 12 ou une forme pharmaceutiquement acceptable de celui-ci pour son utilisation selon l'une quelconque des revendications 1 à 12.

10

15

20

25

30

35

40


45

50

55


**Figure 1**

Urinary glucose concentration (mM)




**Figure 2**

Compound A plasma exposure (nM)




**Figure 3**

Plasma glucose (mM)



**Figure 4**

Plasma glucose (mM)



**Figure 5**

Plasma insulin ( $\mu\text{IU/mL}$ )




Figure 6







Figure 7



**Figure 8**




**Figure 9**



**Figure 10**

**A**

Plasma NEFA ( $\mu\text{Eq/L}$ )



**B**

Plasma NEFA ( $\mu\text{Eq/L}$ )




Figure 11




Figure 12




Figure 13





Figure 14



**REFERENCES CITED IN THE DESCRIPTION**

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

**Patent documents cited in the description**

- WO 2007128749 A1 [0007]
- WO 2010092123 A1 [0007]
- WO 0127128 A [0046] [0220]
- WO 03099836 A [0046] [0048] [0220]
- WO 2005092877 A [0046] [0050] [0220]
- WO 2006034489 A [0046] [0220]
- WO 2006064033 A [0046] [0220]
- WO 2006117359 A [0046] [0050] [0220]
- WO 2006117360 A [0046] [0220]
- WO 2007025943 A [0046] [0220]
- WO 2007028814 A [0046] [0220]
- WO 2007031548 A [0046] [0220]
- WO 2007093610 A [0046] [0220]
- WO 2007128749 A [0046] [0136] [0220]
- WO 2008049923 A [0046] [0220]
- WO 2008055870 A [0046] [0220]
- WO 2008055940 A [0046] [0220]
- WO 2009022020 A [0046] [0220]
- WO 2009022008 A [0046] [0220]
- WO 2005012326 A [0047] [0049] [0052] [0220]
- WO 2008116179 A [0048] [0220]
- WO 2008002824 A [0048] [0220]
- WO 2009035969 A [0049] [0220]
- WO 2008069327 A [0049] [0220]
- WO 2006120208 A [0050] [0220]
- WO 2011039108 A [0050] [0220]
- WO 2011039107 A [0050] [0220]
- WO 2004007517 A [0051] [0220]
- WO 2004080990 A [0052] [0220]
- WO 2007114475 A [0052] [0220]
- WO 2007140191 A [0053] [0220]
- WO 2008013280 A [0053] [0220]
- WO 2010023594 A [0055] [0220]
- EP 1213296 A [0056] [0220]
- EP 1354888 A [0056] [0220]
- EP 1344780 A [0057] [0220]
- EP 1489089 A [0057] [0220]
- WO 2008042688 A [0058] [0220]
- WO 2009014970 A [0058] [0220]
- WO 2014016381 A [0089] [0220]

**Non-patent literature cited in the description**

- **FRANK et al.** *Journal of Veterinary Internal Medicine*, 2010, vol. 24 (3), 467-75 [0220]